A method for the treatment of chronic hand eczema in patients with moderate to severe chronic hand eczema
Patent Information
- Application Number
- HK62026124651
- Authority / Receiving Office
- HK · HK
- Patent Type
- Applications
- Current Assignee / Owner
- Priority Date
- 2023-12-07
- Filing Date
- 2026-06-10
- Publication Date
- 2026-09-11
AI Technical Summary
Existing treatments are ineffective in managing moderate to severe chronic hand eczema, and existing therapies have safety concerns or limitations in long-term use, leading to a decline in patients' quality of life.
An acidified aqueous topical composition containing 20 mg/g digotinib is applied twice daily to the patient's skin to treat moderate to severe chronic hand eczema. It reduces inflammation and immune response by blocking multiple cytokine-mediated signaling pathways.
It significantly improves the severity of the disease and the quality of life of patients, reduces itching and pain symptoms, improves patients' daily living functions, has a good safety profile, and is suitable for long-term use.
Smart Images

Figure 00000098_0000 
Figure 00000099_0000 
Figure 00000099_0001
Abstract
Description
TECHNICAL FIELD
[0001] The present invention relates to a method of treating chronic hand eczema in a human patient, comprising administering to the skin of said human patient an acidified aqueous topical formulation comprising delgocitinib. BACKGROUND
[0002] Chronic hand eczema (CHE) is a severe inflammatory skin disease located on any part of the hands or wrists. It is clinically characterized by erythema, infiltration, hyperkeratosis, edema, and vesicles. Secondary signs include scaling, fissuring, and erosion, and the condition can be exacerbated by bacterial infection. Important symptoms include pruritus and pain, and the disease is often characterized by chronic relapse and poor prognosis.
[0003] CHE refers to hand eczema with a duration of more than 3 months or with two or more relapses within 12 months.
[0004] Hand eczema is usually caused by a multitude of factors, and it is generally accepted that there is no simple relationship between clinical patterns and etiological diagnosis (J Eur Acad Dermatol Venereol. 2015;29(12):2417-2422).
[0005] A number of different classifications have been proposed (Diepgen et al., J Dtsch Dermatol Ges. 2015;13(l):el-22, Cronin E et al., Contact Dermatitis. 1985;13(3):153-161, Johansen et al., Contact Dermatitis. 2011;65(l):13-21), and it was found that the most common CHE subtypes are irritant contact dermatitis, atopic hand eczema, and hyperkeratotic eczema (Apfelbacher et al., Acta Derm Venereol. 2014;94(2):163-167).
[0006] Other subtypes include allergic contact dermatitis, contact urticaria / protein contact dermatitis, and recurrent vesicular hand eczema (pompholyx).
[0007] Prevalence and incidence of hand eczema reported vary greatly, depending on the method of data collection. In a review of available data from 1964 to 2007, the point prevalence of hand eczema in the general population was about 4%, the 1-year prevalence was about 10%, and the lifetime prevalence was close to 15%, with about 7-10% of hand eczema patients reporting symptoms 'almost all the time', which means that the disease is in a chronic state. Based on data from 7 studies, the incidence of hand eczema was 5.5 cases per 1000 person years, with a higher median incidence in women (Diepgen et al., J Dtsch Dermatol Ges. 2015; 13(l):el-22). A number of risk factors have been identified, such as the presence of AD earlier in life, female sex, wet work, and contact allergy (Thyssen et al., Contact Dermatitis. 2010; 62(2):75-87, Mortz et al., Br J Dermatol. 2014; 171(2):313-323).
[0008] The prevalence of hand eczema varies between different age groups (6), with a mean / median age of onset of 20 years or mid-20s (Anveden et al., Contact Dermatitis. 2006; 54(5):272-277, Hald et al., Br J Dermatol. 2008; 158(4):773-777, Lind et al., Occup Environ Med. 2007; 64(3): 191-195). However, about one-third of both men and women report that they first experienced hand eczema before the age of 20 (Meding B et al., J Invest Dermatol. 2004; 122(4):873-877).
[0009] While the underlying molecular mechanisms of CHE are not fully understood, a number of cytokine-mediated signaling cascades have been identified as part of the pathophysiology, including cytokine responses representing the Th2 pathway (IL-4, IL-13), the Th22 pathway (IL-22), the Thl 7 pathway (IL-17), the Thl pathway (interferon-gamma), and the JAK / STAT pathway. Since JAK proteins are required for signaling of most cytokines, blocking JAK reduces cytokine signaling and thereby breaks the vicious cycle that leads to the development of CHE (Pedersen et al., J Invest Dermatol. 2007; 127(11):2585-2595, Brunner et al., J Allergy Clin Immunol. 2017; 139(4S):S65-S76, Gittler et al., Journal of Allergy and Clinical Immunology. 2013; 131(2):300-313).
[0010] CHE is often difficult to treat and can exhibit periods of flares and periods of remission.
[0011] Treatment of CHE involves different disease management strategies, such as elimination of triggers in a stepwise manner, general skin care, and anti-inflammatory therapy. General skin care in the form of emollients is widely used and recommended by physicians, but evidence of its efficacy is sparse. Elimination of triggers such as allergens and irritants can be effective and is a necessary prerequisite for long-term successful therapy, but in many cases elimination can be difficult to achieve. Despite the lack of documented treatment effect, TCS remains the backbone of topical anti-inflammatory therapy for hand eczema. However, long-term use of TCS is limited due to side effects such as skin atrophy and potential suppression of skin barrier repair.
[0012] While mild CHE can be managed to some extent by elimination of triggers and general skin care, management of moderate to severe CHE is more problematic. Alitretinoin is the only product specifically indicated for the treatment of CHE, but is only indicated for the treatment of severe CHE and is approved in only a few countries globally. Alitretinoin treatment has various safety limitations and is therefore only indicated for severe CHE adults who have failed to respond to potent TCS therapy.
[0013] Given the paucity of approved therapies for the treatment of CHE, other treatment options are limited to those approved for other skin diseases with inflammatory pathophysiology. These applications lack clinical documentation for CHE and are limited to short-term use, which is not suitable for a chronic disease characterized by relapsing features, which often requires long-term treatment exposure.
[0014] Due to the lack of documented therapeutic effect of currently available treatment options or the limitation of long-term use due to safety concerns, there is a high unmet medical need for new topical treatments for moderate to severe CHE, which need to be highly effective and have a good safety profile, especially for long-term use. New and better treatments could potentially improve the daily life of patients suffering from moderate to severe CHE. Diclofenac is expected to address the unmet medical need associated with this severe disease.
[0015] Diclofenac is disclosed in WO2011013785 and has the general formula
[0016]
[0017] and can be suitably prepared by one of the methods disclosed in WO2018117152.
[0018] Diclofenac is a pan-JAK inhibitor that blocks multiple cytokine-mediated signaling pathways and broadly inhibits the activation of immune and inflammatory cells such as T cells, B cells, mast cells, and monocytes activated by these cytokines.
[0019] The efficacy and safety of diclofenac in mild to severe CHE has been demonstrated in a phase 2a trial with diclofenac 30 mg / g and a phase 2b dose ranging trial with diclofenac (1, 3, 8 and 20 mg / g) (Worm et al., British Journal of Dermatology (2022), 187, p-42-51 and British Journal of Dermatology (May 2020, 185, (5), 1103-1110).
[0020] In the treatment of patients with moderate to severe CHE, there is an apparent unmet need for new long-term treatment options.
[0021] It has now been found that acidified aqueous compositions comprising diclofenac have a significant effect in patients with moderate to severe chronic hand eczema (CHE). SUMMARY
[0022] The present invention relates to a method of treating moderate to severe chronic hand eczema in a human patient in need thereof, the method comprising applying to the skin of said human patient twice daily an acidified aqueous topical composition comprising 20 mg / g of deguelin on a free base basis or a pharmaceutically acceptable salt thereof, wherein the patient has a disease severity graded as moderate to severe according to IGA-CHE at screening and at baseline (i.e. IGA-CHE score of 3 or 4).
[0023] In another aspect, the present invention relates to said acidified aqueous topical composition for use in a method of treating moderate to severe chronic hand eczema. DETAILED DESCRIPTION BRIEF DESCRIPTION OF DRAWINGS
[0024] Figure 1 : IGA-CHE TS responders from week 0 to week 16. a) IGA-CHE TS by visit, b) TS defined as IGA CHE score of 0 (clear) or 1 (almost clear) and with >2 step improvement compared to baseline.
[0025] Figure 2A , 2B and 2C: HECSI75 as percentage of responders from week 0 to week 16 (2A), HECSI90 and DLQI > 4 as percentage of responders from week 0 to week 16 (2B), and HECSI75, HECSI90 and DLQI > 4 as percentage of responders at week 16 (2C).
[0026] Figure 3 . Change in HESD pain score (weekly mean) from baseline to week 16 in DELTA 1 and DELTA 2 (full analysis set, WOCF). HESD pain score was reported by study participants daily and ranged from 0 (‘no symptoms’) to 10 (‘severe symptoms’).
[0027] Figure 4A and B. Proportion of patients achieving (A) HESD pain >4-point reduction and (B) HESD pruritus >4-point reduction from baseline to week 16 in study participants, with corresponding baseline HESD pain / pruritus score (weekly mean) >4 points in DELTA 1 and DELTA 2 (full analysis set, NRI), (A) HESD pain >4-point reduction. Figure 4 (B) HESD pruritus >4-point reduction. HESD pruritus and pain score were reported by study participants daily and ranged from 0 (‘no symptoms’) to 10 (‘severe symptoms’).
[0028] Figure 5 . Change from baseline to Week 16 in HESD pruritus score (weekly mean) in DELTA 1 and DELTA 2 (Full Analysis Set, WOCF). HESD pruritus score was reported by study participants daily and ranged from 0 ('no symptoms') to 10 ('severe symptoms').
[0029] Figure 6 . Summary of adverse events in DELTA 1 and DELTA 2 (Safety Analysis Set). Includes AEs with onset on or after the date of first study treatment application, or AEs that worsened in severity after first study treatment application. Categorized according to MedDRA version 24.0. a Exacerbation or worsening of CHE beyond normal fluctuation or in areas not typically affected by CHE was reported.
[0030] Figure 7 . Outcome and measures taken after an adverse event occurred in DELTA 1 and DELTA 2 (Safety Analysis Set) using study medication.
[0031] Figure 8 . Relative (percent of positive control) individual and mean effect of ointment and cream on human skin explants (Native Skin) at 24 hours post-treatment. Different colors represent different donors for each treatment.
[0032] Figure 9 . Open flow microperfusion probe inserted in the dermis.
[0033] Figure 10 . Change from baseline in EQ-5D at Week 16 in all patients and change in treatment response assessed by HECSI, IGA-CHE, and HEDS pruritus and pain scores.
[0034] Figure 11 . Change from baseline in DLQI at Week 16 in all patients and change in treatment response assessed by HECSI, IGE-CHE, and HEDS pruritus and pain scores.
[0035] Figure 12 . Proportion of patients achieving HESD pruritus >4-point improvement and HESD pain >4-point improvement over time - pooled data from DELTA 1 and DELTA 2. *Statistical significance compared to vehicle adjusted for multiplicity, **Statistical significance compared to vehicle not adjusted for multiplicity. Based on the number of patients with baseline value >4 (range from 0-10).
[0036] Abbreviations
[0037] AE = adverse event;
[0038] CHE = chronic hand eczema;
[0039] cDLQI = children’s dermatology life quality index;
[0040] HECSI = hand eczema severity index;
[0041] HECSI-75 = at least 75% improvement from baseline in HECSI score
[0042] HECSI-90 = at least 90% improvement from baseline in HECSI score;
[0043] HESD = hand eczema symptom diary © .
[0044] IE = incident event;
[0045] IGA-CHE = investigator’s global assessment of chronic hand eczema © ;
[0046] IGA-CHE TS = IGA-CHE treatment success, i.e., IGA-CHE score of 0 (clear) or 1 (almost clear) with > 2-step improvement from baseline;
[0047] TS = treatment success.
[0048] DLQI = dermatology life quality index;
[0049] EQ-5D-5L = EuroQol 5-Dimensions Health Questionnaire 5-level;
[0050] HEIS = hand eczema impact scale;
[0051] PDAL = proximal daily activity limitation
[0052] WPAI:CHE = work productivity and activity impairment: chronic hand eczema.
[0053] cDLQI = children’s dermatology life quality index;
[0054] AS = area score; SS = severity score;
[0055] CI, confidence interval;
[0056] LS, least squares;
[0057] SE, standard error;
[0058] WOCF, worst observation carry forward;
[0059] NRI, non-responder imputation;
[0060] E, number of events;
[0061] N, number of patients in the analysis set;
[0062] n, number of patients with observations;
[0063] PYO, patient years of observation; R, rate calculated as (E / PYO)*100.
[0064] As used herein, about in relation to a value or amount means + / - 10% of the value or amount.
[0065] Efficacy Measures
[0066] IGA-CHE
[0067] IGA-CHE rates the overall severity of disease in a subject and is based on a 5- point scale ranging from 0 (cleared) to 4 (severe) (Table 1). The assessment will be based on the disease condition at the time of evaluation and is independent of the condition at the previous visit. New lesions appearing on previously untreated areas will be included in the assessment.
[0068]
[0069] Table 1
[0070] Hand Eczema Severity Index (HECSI)
[0071] HECSI is a tool used in clinical trials to rate the severity of 6 clinical symptoms (erythema, infiltration / papules, vesicles, fissures, scaling, and edema) and the extent of lesions on each of 5 hand areas (fingertip, finger [excluding fingertip], palm, back of hand, and wrist) using a standard scale (Held et al., Br J Dermatol. 2005; 152(2):302-307).
[0072] For each hand region (both hands total, e.g., 10 fingers), the investigators rated the average severity of each of the 6 clinical signs of hand eczema using a 4-point severity scale ranging from 0 (none / absent) to 3 (severe) (Table 2). The investigators also rated the extent of the lesions by assessing the percentage of the hand region they occupied and converting this to a score based on a 5-point scale (area score) (Table 2). For each hand region, the regional score will be calculated by adding the severity scores of the 6 clinical signs of hand eczema and multiplying by the area score (Table 3). The HECSI score is equal to the sum of the regional scores and ranges from 0 (the lowest possible score) to 360 (the highest possible score).
[0073] The assessment will be based on the disease status at the time of the evaluation and is independent of the status at the previous visit. New CHE lesions appearing on previously untreated areas will be included in the assessment.
[0074] Table 2: HECSI severity score scale and area score scale
[0075]
[0076] Table 3: Calculation of total HECSI score
[0077]
[0078] Patient-Reported Outcomes (Efficacy)
[0079] The PRO HESD is considered an efficacy assessment.
[0080] Hand Eczema Symptom Diary (HESD)
[0081] The HESD is a 6-item PRO instrument designed to assess the severity of CHE signs and symptoms. Subjects will assess the most severe degree of 6 separate signs and symptoms of CHE (itching, pain, cracking, redness, dryness, and flaking) over the past 24 hours using an 11-point numerical rating scale, where 0 =‘none (symptom)’ and 10 =‘severe (symptom)’. The HESD score is obtained as the mean of the 6 items.
[0082] Safety assessments
[0083] Patient-Reported Outcomes (Health-Related Quality of Life and Work Productivity)
[0084] Patient Global Impression of Severity (PGI-S) Questionnaire
[0085] PGI-S is a one-item questionnaire designed to assess the subject's overall impression of the severity of their pruritus, pain, or signs and symptoms of chronic hand eczema over the past week based on a 4-point categorical response scale ('none','mild','moderate', or'severe'), Table 4.
[0086] Table 4: Patient's Global Impression of Severity (PGI-S) questionnaire
[0087]
[0088] Patient Global Impression of Change (PGI-C) Questionnaire
[0089] PGI-C is a one-item questionnaire designed to assess the subject's impression of change (38). The subject must select a response from 5 response options ('much better', 'a little better', 'no change', 'a little worse', or'much worse') that best describes their overall change in pruritus, pain, or signs and symptoms of chronic hand eczema since they started IMP treatment, Table 5.
[0090] Table 5: Patient's Global Impression of Change (PGI-C) questionnaire
[0091]
[0092] Hand Eczema Impact Scale (HEIS)
[0093] The HEIS consists of 9 items that address the subject's perception of the impact of hand eczema on their daily activities, embarrassment, frustration, sleep, work, and physical functioning over the past 7 days. Each item is scored on a 5-point scale (0 = 'not at all', 1 = 'a little', 2 ='moderate', 3 = 'a lot', 4 = 'extreme'). The HEIS score is the mean of the 9 items. The highest possible score is 4, and a high score indicates a large impact. Six domain scores can be calculated for the HEIS: PDAL (mean of 3 items), embarrassment of hand appearance (mean of 2 items), frustration with CHE (1 item), sleep (1 item), work (1 item), and physical functioning (1 item).
[0094] Patient's Global Assessment of Disease Severity (PaGA)
[0095] The subject will make a global assessment of the severity of their hand eczema. The assessment will be made on a 5-point scale (0 = 'clear', 1 = 'almost clear', 2 ='mild', 3 ='moderate', 4 ='severe') and will be based on the severity of the hand eczema at the time of assessment, Table 6.
[0096] Table 6: Patient's Global Assessment of Disease Severity (PaGA)
[0097]
[0098] Dermatology Life Quality Index (DLQI)
[0099] The DLQI is a validated questionnaire specifically for patients with skin disease. It consists of 10 items that relate to the subject's perception of the impact of their skin disease on different aspects of their quality of life over the past week, such as symptoms and feelings associated with the skin disease, daily activities, leisure, work or school, personal relationships and treatment (39). Each item is scored on a 4-point Likert scale (0 = 'not at all / relevant'; 1 = 'a little'; 2 = 'a lot'; 3 ='very much'). The DLQI score is the sum of the 10 items (score range from 0 to 30); a high score indicates a poor quality of life.
[0100] The cDLQI is a validated questionnaire specifically for patients with skin disease. It consists of 10 items that relate to the subject's perception of the impact of their skin disease on different aspects of their quality of life over the past week, such as symptoms and feelings associated with the skin disease, friendships, leisure, school or holidays, negative comments, sleep and treatment (35). Each item is scored on a 4-point Likert scale (0 = 'not at all / relevant'; 1 = 'a little'; 2 = 'a lot'; 3 ='very much'). The total score is the sum of the 10 items (0 to 30); a high score indicates a poor quality of life.
[0101] EuroQol 5-Dimensions Health Questionnaire 5-level (EQ-5D-5L)
[0102] The EQ-5D-5L is a standardized measure of health status developed by the EuroQol Group to provide a simple, generic measure of health for the clinical and economic evaluation of health care (EuroQol--a new facility for the measurement of health-related quality of life. Health Policy. 1990;16(3):199-208).
[0103] The EQ-5D-5L is a self-completion questionnaire used to assess 'today' health status and is divided into 2 parts.
[0104] The first part consists of 5 dimensions (mobility, self-care, usual activities, pain / discomfort, and anxiety / depression). Participants will rate each dimension using a 5-point scale ('no problem','mild problem','moderate problem','severe problem', and 'extreme problem'). The EQ-5D-5L index score is derived from the 5 dimensions and has been converted from the 5L system to the 3L system using the EQ-5D-5L crosswalk value set. The index score ranges from -0.594 to 1.0 (based on the UK country-specific value set), with higher scores indicating better health status.
[0105] The second part consists of a vertical visual analogue scale anchored at 0 ('worst health you can imagine') and 100 ('best health you can imagine'). Work productivity and activity impairment: chronic hand eczema (WPAI:CHE).
[0106] The impact of CHE on the ability of the participants to work and perform routine activities will be assessed by the WPAI:CHE, which is a tool that measures impairment in both paid and unpaid work (Reilly et al., Pharmacoeconomics. 1993;4(5):353-365). The WPAI:CHE consists of 6 items and scores can be calculated for 4 domains, each reflecting the percentage of impairment due to CHE over the past 7 days, with higher numbers indicating greater impairment and lower productivity:
[0107] • Absenteeism: percentage of work time missed by currently employed persons due to CHE.
[0108] • Presenteeism: percentage of work hours lost due to CHE by currently employed and actually working persons over the past 7 days.
[0109] • Work productivity loss: percentage of overall work lost due to CHE by currently employed persons.
[0110] • Activity impairment: percentage of activity impairment due to CHE by all respondents.
[0111] The endpoints to be investigated are shown in Table 7 and Table 8 below.
[0112] Table 7: Primary endpoints
[0113]
[0114] Table 8: Secondary and exploratory endpoints
[0115]
[0116]
[0117] Table 9: Primary, key secondary and secondary endpoints
[0118]
[0119] Table 10: Secondary and exploratory endpoints
[0120]
[0121] As described above, the present application relates to: a method of treating moderate to severe chronic hand eczema in a human patient, comprising administering to the skin of said human patient in need thereof twice a day an acidified aqueous topical composition comprising 20 mg / g of digoxin based on free base or a pharmaceutically acceptable salt thereof, wherein the patient has a disease severity graded as moderate to severe according to IGA-CHE (i.e. IGA-CHE score of 3 or 4) at screening and at baseline.
[0122] In a further embodiment, the present application relates to: the use of an acidified aqueous topical composition for the treatment of moderate to severe chronic hand eczema in a human patient, comprising administering to the skin of said human patient in need thereof twice a day, the acidified aqueous topical composition comprising 20 mg / g of digoxin based on free base or a pharmaceutically acceptable salt thereof, wherein the patient has a disease severity graded as moderate to severe according to IGA-CHE (i.e. IGA-CHE score of 3 or 4) at screening and at baseline.
[0123] In a further embodiment, the present application relates to: the use of digoxin for the manufacture of an acidified aqueous topical composition for the treatment of moderate to severe chronic hand eczema in a human patient, comprising administering to the skin of said human patient in need thereof twice a day, the composition comprising 20 mg / g of digoxin based on free base or a pharmaceutically acceptable salt thereof, wherein the patient has a disease severity graded as moderate to severe according to IGA-CHE (i.e. IGA-CHE score of 3 or 4) at screening and at baseline.
[0124] In a further embodiment, the present application relates to the above method, use or use, wherein the patient has a HESD pruritus score (weekly mean) of >4 at baseline.
[0125] In a further embodiment, the present application relates to the above method, use or use, wherein the patient: is an adolescent of 12 to 17 years or an adult of 18 years or older; wherein the patient has hand eczema lasting more than 3 months or hand eczema that has relapsed two or more times in the past 12 months.
[0126] In a further embodiment, the present application relates to the above method, use or use, wherein the patient has a documented history of inadequate response to topical corticosteroid (TCS) treatment, or for whom TCS is documented as medically inadvisable for other reasons (due to major side effects or safety risks).
[0127] In a further embodiment, the present application relates to the above method, use or use, wherein at week 16, the patient achieves an IGA-CHE score of 0 (cleared) or 1 (almost cleared) and an improvement of >2 steps relative to baseline.
[0128] In a further embodiment, the present application relates to the above method, use or use, wherein at week 12, the patient achieves an IGA-CHE score of 0 (cleared) or 1 (almost cleared) and an improvement of >2 steps relative to baseline.
[0129] In a further embodiment, the present application relates to the above method, use or use, wherein at week 8, the patient achieves an IGA-CHE score of 0 (cleared) or 1 (almost cleared) and an improvement of >2 steps relative to baseline.
[0130] In a further embodiment, the present application relates to the above method, use or use, wherein at week 4, the patient achieves an IGA-CHE score of 0 (cleared) or 1 (almost cleared) and an improvement of >2 steps relative to baseline.
[0131] In a further embodiment, the present application relates to the above method, use or use, wherein at week 2, the patient achieves an IGA-CHE score of 0 (cleared) or 1 (almost cleared) and an improvement of >2 steps relative to baseline.
[0132] In a further embodiment, the present application relates to the above method, use or use, wherein at week 1, the patient achieves an IGA-CHE score of 0 (cleared) or 1 (almost cleared) and an improvement of >2 steps relative to baseline.
[0133] In a further embodiment, the present application relates to the above method, use or use, wherein at week 16, or week 8, or week 4, week 2 or week 1, the patient achieves at least 90% improvement in HECSI score relative to baseline.
[0134] In a further embodiment, the present application relates to the above method, use or use, wherein at week 16, or week 0 or week 8, or week 4, or week 2 or week 1, the patient achieves at least 75% improvement in HECSI score relative to baseline.
[0135] In a further embodiment, the present application relates to the above method, use or use, wherein the patient has a baseline HESD score (weekly mean) of > 4 points and achieves a reduction of > 4 points in the HESD score (weekly mean) from baseline at week 16.
[0136] In a further embodiment, the present application relates to the above method, use or use, wherein the patient has a baseline HESD score (weekly mean) of > 4 points and achieves a reduction of > 4 points in the HESD score (weekly mean) from baseline at week 12.
[0137] In a further embodiment, the present application relates to the above method, use or use, wherein the patient has a baseline HESD score (weekly mean) of > 4 points at baseline and achieves a reduction of > 4 points in the HESD score (weekly mean) from baseline at week 8.
[0138] In a further embodiment, the present application relates to the above method, use or use, wherein the patient has a baseline HESD score (weekly mean) of > 4 points at baseline and achieves a reduction of > 4 points in the HESD score (weekly mean) from baseline at week 4.
[0139] In a further embodiment, the present application relates to the above method, use or use, wherein the patient has a baseline HESD score (weekly mean) of > 4 points at baseline and achieves a reduction of > 4 points in the HESD score (weekly mean) from baseline at week 2.
[0140] In a further embodiment, the present application relates to the above method, use or use, wherein the patient has a baseline HESD score (weekly mean) of > 4 points at baseline and achieves a reduction of > 4 points in the HESD score (weekly mean) from baseline at week 1.
[0141] In a further embodiment, the present application relates to the above method, use or use, wherein the patient has a baseline HESD score (weekly mean) of > 3 points and achieves a reduction of > 3 points in the HESD score (weekly mean) from baseline at week 16.
[0142] In a further embodiment, the present application relates to the above method, use or use, wherein the patient has a baseline HESD score (weekly mean) of > 3 points and achieves a reduction of > 3 points in the HESD score (weekly mean) from baseline at week 12.
[0143] In a further embodiment, the present application relates to the above method, use or use, wherein the patient has a baseline HESD score (weekly mean) of > 3 points at baseline and achieves a reduction of > 3 points in the HESD score (weekly mean) from baseline at week 8.
[0144] In a further embodiment, the present application relates to the above method, use or use, wherein the patient has a baseline HESD score (weekly mean) of > 3 points at baseline and achieves a reduction of > 3 points in the HESD score (weekly mean) from baseline at week 4.
[0145] In a further embodiment, the present application relates to the above method, use or use, wherein the patient has a baseline HESD score (weekly mean) of > 3 points at baseline and achieves a reduction of > 3 points in the HESD score (weekly mean) from baseline at week 2.
[0146] In a further embodiment, the present application relates to the above method, use or use, wherein the patient has a baseline HESD score (weekly mean) of > 3 points at baseline and achieves a reduction of > 3 points in the HESD score (weekly mean) from baseline at week 1.
[0147] In a further embodiment, the present application relates to the above method, use or use, wherein the patient has a baseline HESD score (weekly mean) of > 3 points at baseline and achieves a reduction of > 3 points in the HESD score (weekly mean) from baseline at week 1.
[0148] In a further embodiment, the present application relates to the above method, use or use, wherein the patient has a baseline HESD score (weekly mean) of > 3 points at baseline and achieves a reduction of > 3 points in the HESD score (weekly mean) from baseline at week 1.
[0149] In a further embodiment, the present application relates to the above method, use or use, wherein the patient has a baseline HESD score (weekly mean) of > 3 points at baseline and achieves a reduction of > 3 points in the HESD score (weekly mean) from baseline at week 1.
[0150] In a further embodiment, the present application relates to the above method, use or use, wherein the patient has a baseline HESD score (weekly mean) of > 3 points at baseline and achieves a reduction of > 3 points in the HESD score (weekly mean) from baseline at week 1.
[0151] In a further embodiment, the present application relates to the above method, use or use, wherein the patient has a baseline HESD score (weekly mean) of > 3 points at baseline and achieves a reduction of > 3 points in the HESD score (weekly mean) from baseline at week 1.
[0152] In a further embodiment, the present application relates to the above method, use or use, wherein the patient has a baseline HESD pruritus score (weekly mean) of > 4 points and achieves a reduction of > 4 points in the HEDS pruritus score (weekly mean) from baseline at week 1.
[0153] In a further embodiment, the present application relates to the above method, use or use, wherein the patient has a baseline HESD pruritus score (weekly mean) of > 3 points and achieves a reduction of > 3 points in the HESD pruritus score (weekly mean) from baseline at week 16.
[0154] In a further embodiment, the present application relates to the above method, use or use, wherein the patient has a baseline HESD pruritus score (weekly mean) of > 3 points and achieves a reduction of > 3 points in the HESD pruritus score (weekly mean) from baseline at week 12.
[0155] In a further embodiment, the present application relates to the above method, use or use, wherein the patient has a baseline HESD pruritus score (weekly mean) of > 3 points and achieves a reduction of > 3 points in the HESD pruritus score (weekly mean) from baseline at week 8.
[0156] In a further embodiment, the present application relates to the above method, use or use, wherein the patient has a baseline HESD pruritus score (weekly mean) of > 3 points and achieves a reduction of > 3 points in the HESD pruritus score (weekly mean) from baseline at week 4.
[0157] In a further embodiment, the present application relates to the above method, use or use, wherein the patient has a baseline HESD pruritus score (weekly mean) of > 3 points and achieves a reduction of > 3 points in the HESD pruritus score (weekly mean) from baseline at week 2.
[0158] In a further embodiment, the present application relates to the above method, use or use, wherein the patient has a baseline HESD pruritus score (weekly mean) of > 3 points and achieves a reduction of > 3 points in the HESD pruritus score (weekly mean) from baseline at week 1.
[0159] In a further embodiment, the present application relates to the above method, use or use, wherein the patient has a baseline HESD pruritus score (weekly mean) of > 3 points and achieves a reduction of > 3 points in the HESD pruritus score (weekly mean) from baseline at day 6, day 5, day 4, day 3, day 2 or within 36 hours or at day 1 or within 24 hours.
[0160] In a further embodiment, the present application relates to the above method, use or use, wherein the patient has a baseline HESD pain score (weekly mean) of > 4 points and achieves a reduction of > 4 points in the HESD pain score (weekly mean) from baseline at week 16.
[0161] In a further embodiment, the present application relates to the above method, use or use, wherein the patient has a baseline HESD pain score (weekly mean) of > 4 points and achieves a reduction of > 4 points in the HESD pain score (weekly mean) from baseline at week 12.
[0162] In a further embodiment, the present application relates to the above method, use or use, wherein the patient has a baseline HESD pain score (weekly mean) of > 4 points and achieves a reduction of > 4 points in the HESD pain score (weekly mean) from baseline at week 8.
[0163] In a further embodiment, the present application relates to the above method, use or use, wherein the patient has a baseline HESD pain score (weekly mean) of > 4 points and achieves a reduction of > 4 points in the HESD pain score (weekly mean) from baseline at week 4.
[0164] In a further embodiment, the present application relates to the above method, use or use, wherein the patient has a baseline HESD pain score (weekly mean) of > 4 points and achieves a reduction of > 4 points in the HESD pain score (weekly mean) from baseline at week 2.
[0165] In a further embodiment, the present application relates to the above method, use or use, wherein the patient has a baseline HESD pain score (weekly mean) of > 4 points and achieves a reduction of > 4 points in the HESD pain score (weekly mean) from baseline at week 1.
[0166] In a further embodiment, the present application relates to the above method, use or use, wherein the patient has a baseline HESD pain score (weekly mean) of > 3 points and achieves a reduction of > 3 points in the HESD pain score (weekly mean) from baseline at week 16.
[0167] In a further embodiment, the present application relates to the above method, use or use, wherein the patient has a baseline HESD pain score (weekly mean) of > 3 points and achieves a reduction of > 3 points in the HESD pain score (weekly mean) from baseline at week 12.
[0168] In a further embodiment, the present application relates to the above method, use or use, wherein the patient has a baseline HESD pain score (weekly mean) of > 3 points and achieves a reduction of > 3 points in the HESD pain score (weekly mean) from baseline at week 8.
[0169] In a further embodiment, the present application relates to the above method, use or use, wherein the patient has a baseline HESD pain score (weekly mean) of > 3 points and achieves a reduction of > 3 points in the HESD pain score (weekly mean) from baseline at week 4.
[0170] In a further embodiment, the present application relates to the above method, use or use, wherein the patient has a baseline HESD pain score (weekly mean) of > 3 points and achieves a reduction of > 3 points in the HESD pain score (weekly mean) from baseline at week 2.
[0171] In a further embodiment, the present application relates to the above method, use or use, wherein the patient has a baseline HESD pain score (weekly mean) of > 3 points and achieves a reduction of > 3 points in the HESD pain score (weekly mean) from baseline at week 1.
[0172] In a further embodiment, the present application relates to the above method, use or use, wherein the patient has a baseline HESD pain score (weekly mean) of > 3 points and achieves a reduction of > 3 points in the HESD pain score (weekly mean) from baseline at day 6, day 5, day 4, day 3, day 2 or within 36 hours or at day 1 or within 24 hours.
[0173] In a further embodiment, the present application relates to the above method, use or use, wherein the patient achieves a reduction of > 4 points in the DLQI score from baseline at week 16.
[0174] In a further embodiment, the present application relates to the above method, use or use, wherein the patient achieves a reduction of > 4 points in the DLQI score from baseline at week 12.
[0175] In a further embodiment, the present application relates to the above method, use or use, wherein the patient achieves a reduction of > 4 points in the DLQI score from baseline at week 8.
[0176] In a further embodiment, the present application relates to the above method, use or use, wherein the patient achieves a reduction of > 4 points in the DLQI score from baseline at week 4.
[0177] In a further embodiment, the present application relates to the above method, use or use, wherein the patient achieves a reduction of > 4 points in the DLQI score from baseline at week 2.
[0178] In a further embodiment, the present application relates to the above method, use or use, wherein at week 1 the patient achieves a reduction of the DLQI score of >4 points from baseline.
[0179] In a further embodiment, the present application relates to the above method, use or use, wherein no accumulation of dicositibine in vivo is observed.
[0180] In a further embodiment, the present application relates to the above method, use or use, wherein treatment is continued until the patient achieves clearance or near-clearance of the skin.
[0181] In a further embodiment, the present application relates to the above method, use or use, wherein in case of recurrence of signs and symptoms (flares), treatment of the affected areas twice daily is restarted as needed.
[0182] In a further embodiment, the present application relates to the above method, use or use, wherein dicositibine is dissolved in the aqueous phase of the topical formulation.
[0183] In a further embodiment, the present application relates to the above method, use or use, wherein the aqueous topical formulation has a pH lower than about 4.6.
[0184] In a further embodiment, the present application relates to the above method, use or use, wherein the aqueous topical formulation has a pH of about 3.8 to about 4.6.
[0185] In a further embodiment, the present application relates to the above method, use or use, wherein the aqueous topical formulation has a pH of about 4.3 or lower.
[0186] In a further embodiment, the present application relates to the above method, use or use, wherein the aqueous topical formulation has a pH of about 4.2 or lower.
[0187] In a further embodiment, the present application relates to the above method, use or use, wherein the aqueous cream comprises a lipid base.
[0188] In a further embodiment, the present application relates to the above method, use or use, wherein the lipid base is liquid paraffin.
[0189] In some embodiments, the acidified aqueous topical composition or aqueous cream is an oil-in-water emulsion described in WO 2020 / 229622.
[0190] In some embodiments, the acidified topical composition or aqueous cream for use according to the application comprises a substantial amount of water and is acidified to a pH of 3.8 to 4.6, more preferably about 4.2, using a pharmaceutically acceptable acid, such as hydrochloric acid.
[0191] In some embodiments, the acidified aqueous topical composition or aqueous cream for use according to the application comprises one or more base selected from medium chain triglycerides, safflower oil, castor oil, liquid paraffin or mixtures thereof. In some embodiments, the base is liquid paraffin.
[0192] The base is typically present in an amount of about 50 mg / g to about 500 mg / g, about 200 mg / g to about 400 mg / g, about 75 mg / g to about 125 mg / g or about 100 mg / g. Suitably, the base is liquid paraffin.
[0193] In some embodiments, the acidified aqueous topical composition or aqueous cream for use according to the application comprises a surfactant, emulsifier or stabiliser and the surfactant, emulsifier or stabiliser is selected from one or more fatty alcohols, such as cetyl alcohol, stearyl alcohol, cetostearyl alcohol, sorbitan esters, sucrose esters, polyoxyl castor oil or mixtures thereof.
[0194] Typically, the surfactant, emulsifier or stabiliser is present in an amount of 40-150 mg / g, 60-120 mg / g or about 80-100 mg / g.
[0195] Typically, the surfactant, emulsifier or stabiliser can be selected from a fatty alcohol, such as cetostearyl alcohol, and is present in an amount of about 30 mg / g to about 120 mg / g, for example about 50 mg / g to about 90 mg / g, or about 70-75 mg / g. Typically, the surfactant, emulsifier or stabiliser can be selected from cetostearyl alcohol, and is present in an amount of about 70-75 mg / g or about 72 mg / g.
[0196] In some embodiments, the acidified aqueous topical composition or aqueous cream for use according to the application comprises a surfactant, emulsifier or stabiliser and the surfactant, emulsifier or stabiliser is selected from sorbitan esters, sucrose esters, polyoxyl fatty alcohol ethers or mixtures thereof. For example, the surfactant or emulsifier is polyoxyl castor oil.
[0197] Generally, the surfactant, emulsifier, or stabilizer present in an amount of about 10 mg / g to about 30 mg / g, about 14 mg / g to about 22 mg / g, or about 20-22 mg / g is selected from sorbitan esters, sucrose esters, polyoxyl cetylstearyl ether, or mixtures thereof. Generally, the surfactant, emulsifier, or stabilizer is polyoxyl cetylstearyl ether in an amount of about 20-22 mg / g or other fatty alcohol ether in an amount of about 18 mg / g.
[0198] In some embodiments, the acidified aqueous topical composition or aqueous cream for use according to the application comprises a buffering agent or pH adjusting agent. The pharmaceutically acceptable buffering agent or pH adjusting agent can be one or more of a phosphate or citrate, sodium acetate, sodium carbonate, sodium citrate dihydrate, hydrochloric acid, or mixtures thereof. For example, the buffering agent or pH adjusting agent can be one or more of citric acid monohydrate and sodium citrate dihydrate. Generally, a buffering agent selected from a phosphate, citrate, or acetate buffer is used.
[0199] The buffering agent or pH adjusting agent can be present in various amounts of about 0.5 mg / g to about 4 mg / g, or about 0.7 mg / g to about 2 mg / g, or about 1 g / g.
[0200] Generally, the buffering agent is a citric acid buffer comprising citric acid monohydrate and sodium citrate dihydrate, and the sodium citrate dihydrate is present in an amount of about 0.5 mg / g to about 4 mg / g, about 0.7 mg / g to about 2 mg / g, or about 1 g / g, and the sodium citrate dihydrate is present in an amount of 0 mg / g to about 1 mg / g, 0 mg / g to about 0.5 mg / g, or is absent.
[0201] In some embodiments, the acidified aqueous topical composition or aqueous cream for use according to the application comprises a pharmaceutically acceptable preservative, such as a preservative selected from benzyl alcohol, sodium dehydroacetate, sorbic acid / salt, or mixtures thereof. In one embodiment, the preservative is benzyl alcohol.
[0202] The preservative can be present in various amounts of about 5 mg / g to about 20 mg / g, about 7 mg / g to about 13 mg / g, or in an amount of about 10 mg / g. Generally, the preservative is benzyl alcohol and is present in an amount of about 5 mg / g to about 20 mg / g, about 7 mg / g to about 13 mg / g, or about 10 mg / g.
[0203] In some embodiments, the acidified aqueous topical composition or aqueous cream used according to the present application comprises a pharmaceutically acceptable antioxidant, such as an antioxidant selected from sodium sulfite, disodium ethylenediaminetetraacetate, trisodium ethylenediaminetetraacetate, butylated hydroxyanisole, or mixtures thereof. In one embodiment, the antioxidant is butylated hydroxyanisole.
[0204] The antioxidant can be present in various amounts from about 0.05 mg / g to about 0.3 mg / g, from about 0.1 mg / g to about 0.25 mg / g, or in an amount of about 0.2 mg / g. Typically, the antioxidant is butylated hydroxyanisole and is present in an amount from about 0.05 mg / g to about 0.3 mg / g, from about 0.1 mg / g to about 0.25 mg / g, or about 0.2 mg / g.
[0205] In some embodiments, the acidified aqueous topical composition or aqueous cream used according to the present application comprises a pharmaceutically acceptable chelating agent, such as EDTA, disodium ethylenediaminetetraacetate, EGTA, or ethylenediamine. In one embodiment, the chelating agent is disodium ethylenediaminetetraacetate.
[0206] Typically, the chelating agent is present in various amounts from about 0.05 mg / g to about 1.5 mg / g, from about 0.5 mg / g to about 1 mg / g, or in an amount of about 0.6 mg / g. Typically, the chelating agent is EDTA and is present in an amount from about 0.05 mg / g to about 1.5 mg / g, from about 0.5 mg / g to about 1 mg / g, or about 0.6 mg / g.
[0207] In some embodiments, the acidified aqueous topical composition or aqueous cream used according to the present application comprises a pharmaceutically acceptable acidifying agent, which can be one or more strong acids, such as hydrochloric acid or citric acid.
[0208] In one embodiment, the acidifying agent is hydrochloric acid.
[0209] The acidifying agent can be present in an amount from 1 mg / g to about 25 mg / g, from about 10 mg / g to about 20 mg / g, or about 17.7 mg / g. Typically, the acidifying agent is hydrochloric acid and is present in an amount from 1 mg / g to about 25 mg / g, from about 10 mg / g to about 20 mg / g, or about 17.7 mg / g.
[0210] In some embodiments, the acidified aqueous topical composition or aqueous cream used according to the present application contains purified water, which can be present in various amounts from about 500 mg / g to about 900 mg / g, and for example 760 mg / g.
[0211] In some embodiments, the acidified aqueous topical composition or aqueous cream for use according to the present application comprises 50-500 mg / g of an oily base and 40-150 mg / g of a surfactant, emulsifier or stabilizer.
[0212] In some embodiments, the acidified aqueous topical composition or aqueous cream for use according to the present application comprises 50-500 mg / g of liquid paraffin, 30-120 mg / g of cetostearyl alcohol or another fatty alcohol and 10-30 mg / g of polyoxyl cetostearyl ether or other fatty alcohol ether.
[0213] In some embodiments, the acidified aqueous topical composition or aqueous cream for use according to the present application comprises 200-400 mg / g of an oily base and 60-120 mg / g of a surfactant, emulsifier or stabilizer.
[0214] In some embodiments, the acidified aqueous topical composition or aqueous cream for use according to the present application comprises 200-400 mg / g of liquid paraffin, 50-90 mg / g of cetostearyl alcohol or another fatty alcohol and 14-22 mg / g of polyoxyl cetostearyl ether or other fatty alcohol ether.
[0215] In some embodiments, the acidified aqueous topical composition or aqueous cream for use according to the present application comprises 75-125 mg / g of an oily base and 80-100 mg / g of a surfactant, emulsifier or stabilizer.
[0216] In some embodiments, the acidified aqueous topical composition or aqueous cream for use according to the present application comprises 75-125 mg / g of liquid paraffin, 70-75 mg / g of cetostearyl alcohol or another fatty alcohol and 14-22 mg / g of polyoxyl cetostearyl ether or other fatty alcohol ether.
[0217] In some embodiments, the acidified aqueous topical composition or aqueous cream for use according to the present application comprises 50-500 mg / g of an oily base, 40-150 mg / g of a surfactant, emulsifier or stabilizer and 0.5-4 mg / g of a buffer (sum of acid and base).
[0218] In some embodiments, the acidified aqueous topical composition or aqueous cream for use according to the present application comprises 50-500 mg / g of liquid paraffin, 30-120 mg / g of cetostearyl alcohol or another fatty alcohol and 10-30 mg / g of polyoxyl cetostearyl ether or other fatty alcohol ether and 0.5-4 mg / g of a buffer (sum of base and acid).
[0219] In some embodiments, the acidified aqueous topical composition or aqueous cream for use according to the present application comprises 200-400 mg / g of an oily base, 60-120 mg / g of a surfactant, emulsifier or stabilizer and 0.7-2 mg / g of a citric acid buffer (sum of base and acid) or another suitable buffer.
[0220] In some embodiments, the acidified aqueous topical composition or aqueous cream for use according to the present application comprises 200-400 mg / g of an oily base, 60-120 mg / g of a surfactant, emulsifier or stabilizer and 0.7-2 mg / g of a citric acid buffer (sum of base and acid) or another suitable buffer.
[0221] In some embodiments, the acidified aqueous topical composition or aqueous cream for use according to the present application comprises 75-125 mg / g of an oily base, 80-100 mg / g of a surfactant, emulsifier or stabilizer and about 1 mg / g of a buffer (sum of base and acid).
[0222] In some embodiments, the acidified aqueous topical composition or aqueous cream for use according to the present application comprises 75-125 mg / g of an oily base, 80-100 mg / g of a surfactant, emulsifier or stabilizer and about 1 mg / g of a buffer (sum of base and acid).
[0223] In some embodiments, the acidified aqueous topical composition or aqueous cream for use according to the present application comprises 50-500 mg / g of a liquid paraffin, 30-120 mg / g of a cetylstearyl alcohol or another fatty alcohol and 10-30 mg / g of a polyoxyl cetylstearyl ether or other fatty alcohol ether, 0.5-4 mg / g of a buffer (sum of base and acid) and 1-25 mg / g of an acidifying agent.
[0224] In some embodiments, the acidified aqueous topical composition or aqueous cream for use according to the present application comprises 200-400 mg / g of an oily base, 60-120 mg / g of a surfactant, emulsifier or stabilizer, 0.7-2 mg / g of a buffer (sum of base and acid) or another suitable buffer and 1-25 mg / g of an acidifying agent.
[0225] In some embodiments, the acidified aqueous topical composition or aqueous cream for use according to the present application comprises 200-400 mg / g of liquid paraffin, 50-90 mg / g of cetostearyl alcohol or another fatty alcohol and 14-22 mg / g of polyoxyl cetostearyl ether or other fatty alcohol ether and 0.7-2 mg / g of citric acid buffer (sum of base and acid) or another suitable buffer and 10-20 mg / g of hydrochloric acid or another pharmaceutically acceptable acidifying agent.
[0226] In some embodiments, the acidified aqueous topical composition or aqueous cream for use according to the present application comprises 75-125 mg / g of oily base, 80-100 mg / g of surfactant, emulsifier or stabilizer and about 1 mg / g of buffer (sum of base and acid) and 10-20 mg / g of acidifying agent.
[0227] In some embodiments, the acidified aqueous topical composition or aqueous cream for use according to the present application comprises 75-125 mg / g of liquid paraffin, 70-75 mg / g of cetostearyl alcohol or another fatty alcohol and 14-22 mg / g of polyoxyl cetostearyl ether or other fatty alcohol ether and about 1 mg / g of citric acid buffer (sum of base and acid) or another suitable buffer and 10-20 mg / g of hydrochloric acid or another pharmaceutically acceptable acidifying agent.
[0228] According to any of the above embodiments, the acidified aqueous topical composition or aqueous cream comprising various amounts of oily base, surfactant, emulsifier or stabilizer, buffer, pH adjusting agent and / or acidifying agent also contains a preservative, an antioxidant and / or an acidifying agent.
[0229] The acidified aqueous topical composition or aqueous cream for use according to the present application can be prepared by preparing the water phase and the oil phase separately, then adding the oil phase to the water phase and mixing it.
[0230] Water phase:
[0231] Mix purified water, pH adjusting agent, buffer, acidifying agent, preservative, chelating agent.
[0232] Add digoxin and dissolve in the water phase
[0233] Adjust the pH
[0234] Heat the water phase
[0235] Oil phase:
[0236] Mix liquid paraffin, surfactant, emulsifier, stabilizer, antioxidant.
[0237] Heat the oil phase
[0238] The oil phase is added to the water phase and mixed.
[0239] The mixture is homogenized and cooled. Subsequently the acidified aqueous topical composition or aqueous cream is filled into a container closure.
[0240] Exemplary pharmaceutical formulations for use according to the present application:
[0241] Component amount (mg / g): Diclofenac 20; Liquid paraffin 100; Cetostearyl alcohol 72; Poloxyl 18 cetostearyl ether 18; Benzyl alcohol 10; Citric acid monohydrate 1.0; Butylated hydroxyanisole 0.2, Disodium ethylenediaminetetraacetate 0.6; 3M Hydrochloric acid 17.7 and purified water 760.
[0242] The acidified aqueous topical composition or aqueous cream for use according to the present application can be prepared as follows:
[0243] Water phase:
[0244] Mix the purified water, pH adjuster, buffer, acidifying agent, preservative, chelating agent.
[0245] At a temperature of about 15-25 °C, the drug substance is added and dissolved in the water phase.
[0246] The pH is adjusted to 4.0-4.4.
[0247] The water phase is heated to about 65-75 °C.
[0248] Oil phase:
[0249] Mix the liquid paraffin, surfactant, emulsifier, stabilizer, antioxidant.
[0250] The oil phase is heated to about 65-75 °C.
[0251] The oil phase is added to the water phase and mixed.
[0252] The mixture is homogenized for about 20 minutes and subsequently cooled to about 30 °C. Subsequently the cream is filled into a container closure.
[0253] Further Embodiments
[0254] 1. A method of treating moderate to severe chronic hand eczema in a human patient in need thereof, comprising administering to the skin of the human patient twice daily an acidified aqueous topical composition comprising 20 mg / g diclofenac on a free base basis or a pharmaceutically acceptable salt thereof, wherein the patient has a disease severity graded as moderate to severe according to IGA-CHE at screening and at baseline.
[0255] 2. The method of embodiment 1, wherein the patient has a HESD pruritus score (weekly mean) of >4 at baseline.
[0256] 3. The method of any one of embodiments 1-2, wherein the patient: is a teenager between 12 and 17 years of age or an adult 18 years of age or older; wherein the patient has hand eczema that has persisted for more than 3 months or hand eczema that has recurred two or more times in the past 12 months.
[0257] 4. The method of any one of embodiments 1-3, wherein the patient has a documented history of inadequate response to topical corticosteroid (TCS) therapy, or TCS is documented as medically inadvisable for the patient for other reasons (e.g., due to major side effects or safety risks).
[0258] 5. The method of any one of embodiments 1-4, wherein the decernotinib is dissolved in the aqueous phase of the acidified aqueous topical formulation.
[0259] 6. The method of embodiment 5, wherein the acidified aqueous topical formulation has a pH of less than about 4.6 or less than about 4.4.
[0260] 7. The method of embodiment 6, wherein the acidified aqueous topical formulation has a pH of about 3.8 to about 4.6.
[0261] 8. The method of embodiment 7, wherein the aqueous topical formulation has a pH of about 4.3 or less.
[0262] 9. The method of embodiment 8, wherein the aqueous topical formulation has a pH of about 4.2 or less.
[0263] 10. The method of any one of embodiments 5-9, wherein the aqueous cream comprises a lipid base.
[0264] 11. The method of embodiment 10, wherein the lipid base is liquid paraffin.
[0265] 12. The method of any one of embodiments 1-11, wherein at week 16, the patient achieves an IGA-CHE score of 0 (cleared) or 1 (nearly cleared) and an improvement of >2 steps relative to baseline.
[0266] 13. The method of embodiment 12, wherein at week 8, the patient achieves an IGA-CHE score of 0 (cleared) or 1 (nearly cleared) and an improvement of >2 steps relative to baseline.
[0267] 14. The method of embodiment 12, wherein at week 4, the patient achieves an IGA-CHE score of 0 (cleared) or 1 (nearly cleared) and an improvement of >2 steps relative to baseline.
[0268] 15. The method of embodiment 12, wherein at week 2, the patient achieves an IGA-CHE score of 0 (cleared) or 1 (nearly cleared) and an improvement of >2 steps relative to baseline.
[0269] 16. The method of embodiment 12, wherein at week 1, the patient achieves an IGA-CHE score of 0 (cleared) or 1 (nearly cleared) and an improvement of >2 steps relative to baseline.
[0270] 17. The method of embodiment 12, wherein at day 5 or day 6, the patient achieves an IGA-CHE score of 0 (cleared) or 1 (nearly cleared) and an improvement of >2 steps relative to baseline.
[0271] 18. The method of embodiment 12, wherein at day 4, the patient achieves an IGA-CHE score of 0 (cleared) or 1 (nearly cleared) and an improvement of >2 steps relative to baseline.
[0272] 19. The method of embodiment 12, wherein at day 3, the patient achieves an IGA-CHE score of 0 (cleared) or 1 (nearly cleared) and an improvement of >2 steps relative to baseline.
[0273] 20. The method of embodiment 12, wherein at day 2 or within 36 hours, the patient achieves an IGA-CHE score of 0 (cleared) or 1 (nearly cleared) and an improvement of >2 steps relative to baseline.
[0274] 21. The method of embodiment 12, wherein at day 1 or within 24 hours, the patient achieves an IGA-CHE score of 0 (cleared) or 1 (nearly cleared) and an improvement of >2 steps relative to baseline.
[0275] 22. The method of any one of embodiments 1-21, wherein at week 16, the patient achieves at least a 90% improvement in HECSI score relative to baseline.
[0276] 23. The method of embodiment 22, wherein at week 8, the patient achieves at least a 90% improvement in HECSI score relative to baseline.
[0277] 24. The method of embodiment 22, wherein at week 4, the patient achieves at least a 90% improvement in HECSI score relative to baseline.
[0278] 25. The method of embodiment 22, wherein at week 2, the patient achieves at least a 90% improvement in HECSI score relative to baseline.
[0279] 25. The method of embodiment 22, wherein the patient achieves at least a 90% improvement in HECSI score from baseline at week 1.
[0280] 26. The method of embodiment 22, wherein the patient achieves at least a 90% improvement in HECSI score from baseline at day 6.
[0281] 27. The method of embodiment 22, wherein the patient achieves at least a 90% improvement in HECSI score from baseline at day 5.
[0282] 28. The method of embodiment 22, wherein the patient achieves at least a 90% improvement in HECSI score from baseline at day 4.
[0283] 29. The method of embodiment 22, wherein the patient achieves at least a 90% improvement in HECSI score from baseline at day 3.
[0284] 30. The method of embodiment 22, wherein the patient achieves at least a 90% improvement in HECSI score from baseline at day 2 or within 36 hours.
[0285] 31. The method of embodiment 22, wherein the patient achieves at least a 90% improvement in HECSI score from baseline at day 1 or within 24 hours.
[0286] 32. The method of any one of embodiments 1-31, wherein the patient achieves at least a 75% improvement in HECSI score from baseline at week 16.
[0287] 33. The method of embodiment 32, wherein the patient achieves at least a 75% improvement in HECSI score from baseline at week 8.
[0288] 34. The method of embodiment 32, wherein the patient achieves at least a 75% improvement in HECSI score from baseline at week 4.
[0289] 35. The method of embodiment 32, wherein the patient achieves at least a 75% improvement in HECSI score from baseline at week 2.
[0290] 36. The method of embodiment 32, wherein the patient achieves at least a 75% improvement in HECSI score from baseline at week 1.
[0291] 37. The method of embodiment 32, wherein the patient achieves at least a 75% improvement in HECSI score from baseline at day 6.
[0292] 38. The method of embodiment 32, wherein the patient achieves at least a 75% improvement in HECSI score from baseline at day 5.
[0293] 39. The method of embodiment 32, wherein the patient achieves at least a 75% improvement in HECSI score from baseline at day 4.
[0294] 40. The method of embodiment 32, wherein the patient achieves at least a 75% improvement in HECSI score from baseline at day 3.
[0295] 41. The method of embodiment 32, wherein the patient achieves at least a 75% improvement in HECSI score from baseline at day 2 or within 36 hours.
[0296] 42. The method of embodiment 32, wherein the patient achieves at least a 75% improvement in HECSI score from baseline at day 1 or within 24 hours.
[0297] 43. The method of any one of embodiments 1-42, wherein the patient has a baseline HESD score (weekly mean) of >4 and achieves a reduction of >4 in HESD score (weekly mean) from baseline at week 16.
[0298] 44. The method of embodiment 43, wherein the patient has a baseline HESD score (weekly mean) of >4 and achieves a reduction of >4 in HESD score (weekly mean) from baseline at week 12.
[0299] 45. The method of embodiment 43, wherein the patient has a baseline HESD score (weekly mean) of >4 at baseline and achieves a reduction of >4 in HESD score (weekly mean) from baseline at week 8.
[0300] 46. The method of embodiment 43, wherein the patient has a baseline HESD score (weekly mean) of >4 at baseline and achieves a reduction of >4 in HESD score (weekly mean) from baseline at week 4.
[0301] 47. The method of embodiment 43, wherein the patient has a baseline HESD score (weekly mean) of >4 at baseline and achieves a reduction of >4 in HESD score (weekly mean) from baseline at week 2.
[0302] 48. The method of embodiment 43, wherein the patient has a baseline HESD score (weekly mean) of >4 at baseline and achieves a reduction of >4 in HESD score (weekly mean) from baseline at week 1.
[0303] 49. The method of any one of embodiments 1-48, wherein the patient has a baseline HESD pruritus score (weekly mean) of >4 and achieves a reduction of >4 in the HEDS pruritus score (weekly mean) from baseline at Week 16.
[0304] 50. The method of embodiment 49, wherein the patient has a baseline HESD pruritus score (weekly mean) of >4 and the patient achieves a reduction of >4 in the HEDS pruritus score (weekly mean) from baseline at Week 8.
[0305] 51. The method of embodiment 49, wherein the patient has a baseline HESD pruritus score (weekly mean) of >4 and the patient achieves a reduction of >4 in the HEDS pruritus score (weekly mean) from baseline at Week 4.
[0306] 52. The method of embodiment 49, wherein the patient has a baseline HESD pruritus score (weekly mean) of >4 and the patient achieves a reduction of >4 in the HEDS pruritus score (weekly mean) from baseline at Week 2.
[0307] 53. The method of embodiment 49, wherein the patient has a baseline HESD pruritus score (weekly mean) of >4 and the patient achieves a reduction of >4 in the HEDS pruritus score (weekly mean) from baseline at Week 1.
[0308] 54. The method of embodiment 49, wherein the patient has a baseline HESD pruritus score (weekly mean) of >4 and the patient achieves a reduction of >4 in the HEDS pruritus score (weekly mean) from baseline at Day 6.
[0309] 55. The method of embodiment 49, wherein the patient has a baseline HESD pruritus score (weekly mean) of >4 and the patient achieves a reduction of >4 in the HEDS pruritus score (weekly mean) from baseline at Day 5.
[0310] 56. The method of embodiment 49, wherein the patient has a baseline HESD pruritus score (weekly mean) of >4 and the patient achieves a reduction of >4 in the HEDS pruritus score (weekly mean) from baseline at Day 4.
[0311] 57. The method of embodiment 49, wherein the patient has a baseline HESD pruritus score (weekly mean) of >4 and the patient achieves a reduction of >4 in the HEDS pruritus score (weekly mean) from baseline at Day 3.
[0312] 58. The method of embodiment 49, wherein the patient has a baseline HESD pruritus score (weekly mean) of >4 points, and the patient achieves a reduction of >4 points in the HEDS pruritus score (weekly mean) from baseline at Day 2 or within 36 hours.
[0313] 59. The method of embodiment 49, wherein the patient has a baseline HESD pruritus score (weekly mean) of >4 points, and the patient achieves a reduction of >4 points in the HEDS pruritus score (weekly mean) from baseline at Day 1 or within 24 hours.
[0314] 60. The method of any one of embodiments 1-59, wherein the patient has a baseline HESD pain score (weekly mean) of >4 points, and the patient achieves a reduction of >4 points in the HESD pain score (weekly mean) from baseline at Week 16.
[0315] 61. The method of embodiment 60, wherein the patient has a baseline HESD pain score (weekly mean) of >4 points, and the patient achieves a reduction of >4 points in the HESD pain score (weekly mean) from baseline at Week 8.
[0316] 62. The method of embodiment 60, wherein the patient has a baseline HESD pain score (weekly mean) of >4 points, and the patient achieves a reduction of >4 points in the HESD pain score (weekly mean) from baseline at Week 4.
[0317] 63. The method of embodiment 60, wherein the patient has a baseline HESD pain score (weekly mean) of >4 points, and the patient achieves a reduction of >4 points in the HESD pain score (weekly mean) from baseline at Week 2.
[0318] 64. The method of embodiment 60, wherein the patient has a baseline HESD pain score (weekly mean) of >4 points, and the patient achieves a reduction of >4 points in the HESD pain score (weekly mean) from baseline at Week 1.
[0319] 65. The method of embodiment 60, wherein the patient has a baseline HESD pain score (weekly mean) of >4 points, and the patient achieves a reduction of >4 points in the HEDS pain score (weekly mean) from baseline at Day 6.
[0320] 66. The method of embodiment 60, wherein the patient has a baseline HESD pain score (weekly mean) of >4 points, and the patient achieves a reduction of >4 points in the HEDS pain score (weekly mean) from baseline at Day 5.
[0321] 67. The method of embodiment 60, wherein the patient has a baseline HESD pain score (weekly mean) of >4 and achieves a reduction of >4 in the HEDS pain score (weekly mean) from baseline at Day 4.
[0322] 68. The method of embodiment 60, wherein the patient has a baseline HESD pain score (weekly mean) of >4 and achieves a reduction of >4 in the HEDS pain score (weekly mean) from baseline at Day 3.
[0323] 69. The method of embodiment 60, wherein the patient has a baseline HESD pain score (weekly mean) of >4 and achieves a reduction of >4 in the HEDS pain score (weekly mean) from baseline at Day 2 or within 36 hours.
[0324] 70. The method of embodiment 60, wherein the patient has a baseline HESD pain score (weekly mean) of >4 and achieves a reduction of >4 in the HEDS pain score (weekly mean) from baseline at Day 1 or within 24 hours.
[0325] 71. The method of any one of claims 1-70, wherein the patient achieves a reduction of >4 in the DLQI score from baseline at Week 16.
[0326] 72. The method of claim 71, wherein the patient achieves a reduction of >4 in the DLQI score from baseline at Week 8.
[0327] 73. The method of claim 71, wherein the patient achieves a reduction of >4 in the DLQI score from baseline at Week 4.
[0328] 74. The method of claim 71, wherein the patient achieves a reduction of >4 in the DLQI score from baseline at Week 2.
[0329] 75. The method of claim 71, wherein the patient achieves a reduction of >4 in the DLQI score from baseline at Week 1.
[0330] 77. The method of any one of embodiments 1-75, wherein treatment is continued until the patient achieves clearance or near-clearance of skin.
[0331] 78. The method of embodiment 77, wherein administration is maintained for at least 2 weeks.
[0332] 79. The method of embodiment 77, wherein administration is maintained for at least 4 weeks.
[0333] 80. The method of embodiment 77, wherein administration is maintained for at least 8 weeks.
[0334] 81. The method of embodiment 77, wherein administration is for at least 12 weeks.
[0335] 82. A method of reducing pruritus in a human patient having moderate to severe chronic hand eczema, comprising administering to the skin of the human patient in need thereof twice daily an acidified aqueous topical composition comprising 20 mg / g of digoxin based on free base or a pharmaceutically acceptable salt thereof, wherein the patient has a baseline HESD pruritus score (weekly mean) of >4.
[0336] 83. The method of embodiment 82, wherein the patient: is a teenager between 12 and 17 years of age or an adult 18 years of age or older; wherein the patient has hand eczema that persists for more than 3 months or hand eczema that has recurred two or more times in the past 12 months.
[0337] 84. The method of any one of embodiments 82-83, wherein the patient has a documented history of inadequate response to topical corticosteroid (TCS) treatment, or TCS is documented as medically inadvisable for the patient for other reasons (e.g., due to major side effects or safety risks).
[0338] 85. The method of any one of embodiments 82-84, wherein digoxin is dissolved in the aqueous phase of the acidified aqueous topical formulation.
[0339] 86. The method of embodiment 85, wherein the acidified aqueous topical formulation has a pH of less than about 4.6 or less than about 4.4.
[0340] 87. The method of embodiment 86, wherein the acidified aqueous topical formulation has a pH of about 3.8 to about 4.6.
[0341] 88. The method of embodiment 87, wherein the aqueous topical formulation has a pH of about 4.3 or less.
[0342] 89. The method of embodiment 88, wherein the aqueous topical formulation has a pH of about 4.2 or less.
[0343] 90. The method of any one of embodiments 83-89, wherein the aqueous cream comprises a lipid base.
[0344] 91. The method of any one of embodiments 82-90, wherein at week 8, the patient achieves a reduction of >4 points in the HEDS pruritus score (weekly mean) from baseline.
[0345] 92. The method of embodiment 91, wherein at week 4, the patient achieves a reduction of >4 points in the HEDS pruritus score (weekly mean) from baseline.
[0346] 93. The method of embodiment 91, wherein at week 2, the patient achieves a reduction of >4 points in the HEDS Pruritus Score (weekly mean) from baseline.
[0347] 94. The method of embodiment 91, wherein at week 1, the patient achieves a reduction of >4 points in the HEDS Pruritus Score (weekly mean) from baseline.
[0348] 95. The method of embodiment 91, at day 6, the patient achieves a reduction of >4 points in the HEDS Pruritus Score (weekly mean) from baseline.
[0349] 96. The method of embodiment 91, wherein at day 5, the patient achieves a reduction of >4 points in the HEDS Pruritus Score (weekly mean) from baseline.
[0350] 97. The method of embodiment 91, wherein at day 4, the patient achieves a reduction of >4 points in the HEDS Pruritus Score (weekly mean) from baseline.
[0351] 98. The method of embodiment 91, wherein at day 3, the patient achieves a reduction of >4 points in the HEDS Pruritus Score (weekly mean) from baseline.
[0352] 99. The method of embodiment 91, wherein at day 2 or within 36 hours, the patient achieves a reduction of >4 points in the HEDS Pruritus Score (weekly mean) from baseline.
[0353] 100. The method of embodiment 91, wherein at day 1 or within 24 hours, the patient achieves a reduction of >4 points in the HEDS Pruritus Score (weekly mean) from baseline.
[0354] 101. The method of embodiment 82, wherein the patient achieves a rapid reduction in pruritus.
[0355] 102. The method of any one of embodiments 82-101, wherein the patient achieves a statistically significant reduction in the HEDS Pruritus Score from baseline at day 1 or within 24 hours compared to a patient administered a placebo.
[0356] 103. The method of any one of embodiments 82-101, wherein the patient achieves a reduction of 1 point in the HEDS Pruritus Score from baseline at day 1 or within 24 hours.
[0357] 104. The method of any one of embodiments 82-101, wherein the patient achieves a statistically significant reduction in the HEDS Pruritus Score from baseline at day 2 or within 36 hours compared to a patient administered a placebo.
[0358] 105. The method of any one of embodiments 82-101, wherein the patient achieves a 2-point reduction from baseline in HEDS Pruritus Score at Day 2 or within 36 hours.
[0359] 106. The method of any one of embodiments 82-101, wherein the patient achieves a 3-point reduction from baseline in HEDS Pruritus Score at Week 8.
[0360] 107. The method of any one of embodiments 82-101, wherein the patient achieves a 3-point reduction from baseline in HEDS Pruritus Score at Week 4.
[0361] 108. The method of any one of embodiments 82-101, wherein the patient achieves a 3-point reduction from baseline in HEDS Pruritus Score at Week 2.
[0362] 109. The method of any one of embodiments 82-101, wherein the patient achieves a 3-point reduction from baseline in HEDS Pruritus Score at Week 1.
[0363] 110. The method of any one of embodiments 82-101, wherein the patient achieves a 4-point reduction from baseline in HEDS Pruritus Score at Week 8.
[0364] 111. The method of any one of embodiments 82-101, wherein the patient achieves a 4-point reduction from baseline in HEDS Pruritus Score at Week 4.
[0365] 113. The method of any one of embodiments 82-112, wherein the patient achieves a significant improvement from baseline in IGA-CHE score compared to placebo.
[0366] 114. The method of any one of embodiments 82-113, wherein at Week 8, the patient achieves an IGA-CHE score of 0 (cleared) or 1 (almost cleared) and an improvement of >2 steps from baseline.
[0367] 115. The method of embodiment 114, wherein at Week 4, the patient achieves an IGA-CHE score of 0 (cleared) or 1 (almost cleared) and an improvement of >2 steps from baseline.
[0368] 116. The method of embodiment 114, wherein at Week 2, the patient achieves an IGA-CHE score of 0 (cleared) or 1 (almost cleared) and an improvement of >2 steps from baseline.
[0369] 117. The method of embodiment 114, wherein at Week 1, the patient achieves an IGA-CHE score of 0 (cleared) or 1 (almost cleared) and an improvement of >2 steps from baseline.
[0370] 118. The method of embodiment 114, wherein on day 5 or day 6, the patient achieves an IGA-CHE score of 0 (cleared) or 1 (nearly cleared) and an improvement of >2 steps relative to baseline.
[0371] 119. The method of embodiment 114, wherein on day 4, the patient achieves an IGA-CHE score of 0 (cleared) or 1 (nearly cleared) and an improvement of >2 steps relative to baseline.
[0372] 120. The method of embodiment 114, wherein on day 3, the patient achieves an IGA-CHE score of 0 (cleared) or 1 (nearly cleared) and an improvement of >2 steps relative to baseline.
[0373] 121. The method of embodiment 114, wherein on day 1 or within 24 hours, the patient achieves an IGA-CHE score of 0 (cleared) or 1 (nearly cleared) and an improvement of >2 steps relative to baseline.
[0374] 122. The method of embodiment 114, wherein on day 2 or within 36 hours, the patient achieves an IGA-CHE score of 0 (cleared) or 1 (nearly cleared) and an improvement of >2 steps relative to baseline.
[0375] 123. The method of any one of embodiments 82-122, wherein at week 16, the patient achieves at least a 90% improvement in HECSI score relative to baseline.
[0376] 124. The method of embodiment 123, wherein at week 8, the patient achieves at least a 90% improvement in HECSI score relative to baseline.
[0377] 125. The method of embodiment 123, wherein at week 4, the patient achieves at least a 90% improvement in HECSI score relative to baseline.
[0378] 126. The method of embodiment 123, wherein at week 2, the patient achieves at least a 90% improvement in HECSI score relative to baseline.
[0379] 127. The method of embodiment 123, wherein at week 1, the patient achieves at least a 90% improvement in HECSI score relative to baseline.
[0380] 128. The method of embodiment 123, wherein on day 6, the patient achieves at least a 90% improvement in HECSI score relative to baseline.
[0381] 129. The method of embodiment 123, wherein on day 5, the patient achieves at least a 90% improvement in HECSI score relative to baseline.
[0382] 130. The method of embodiment 123, wherein the patient achieves at least a 90% improvement in HECSI score from baseline on day 4.
[0383] 131. The method of embodiment 123, wherein the patient achieves at least a 90% improvement in HECSI score from baseline on day 3.
[0384] 132. The method of embodiment 123, wherein the patient achieves at least a 90% improvement in HECSI score from baseline on day 2 or within 36 hours.
[0385] 133. The method of embodiment 123, wherein the patient achieves at least a 90% improvement in HECSI score from baseline on day 1 or within 24 hours.
[0386] 134. The method of any one of embodiments 82-122, wherein the patient achieves at least a 75% improvement in HECSI score from baseline at week 16.
[0387] 135. The method of embodiment 134, wherein the patient achieves at least a 75% improvement in HECSI score from baseline at week 8.
[0388] 136. The method of embodiment 134, wherein the patient achieves at least a 75% improvement in HECSI score from baseline at week 4.
[0389] 137. The method of embodiment 134, wherein the patient achieves at least a 75% improvement in HECSI score from baseline at week 2.
[0390] 138. The method of embodiment 134, wherein the patient achieves at least a 75% improvement in HECSI score from baseline at week 1.
[0391] 139. The method of embodiment 134, wherein the patient achieves at least a 75% improvement in HECSI score from baseline on day 6.
[0392] 140. The method of embodiment 134, wherein the patient achieves at least a 75% improvement in HECSI score from baseline on day 5.
[0393] 141. The method of embodiment 134, wherein the patient achieves at least a 75% improvement in HECSI score from baseline on day 4.
[0394] 143. The method of embodiment 134, wherein the patient achieves at least a 75% improvement in HECSI score from baseline on day 3.
[0395] 144. The method of embodiment 134, wherein the patient achieves at least a 75% improvement in HECSI score from baseline by Day 2 or within 36 hours.
[0396] 145. The method of embodiment 134, wherein the patient achieves at least a 75% improvement in HECSI score from baseline by Day 1 or within 24 hours.
[0397] 146. The method of any one of embodiments 82-145, wherein treatment is continued until the patient achieves clearance or near-clearance of the skin.
[0398] 147. The method of any one of embodiments 82-146, wherein administration is for at least 2 weeks.
[0399] 148. The method of embodiment 147, wherein administration is for at least 4 weeks.
[0400] 149. The method of embodiment 147, wherein administration is for at least 8 weeks.
[0401] 150. The method of embodiment 147, wherein administration is for at least 12 weeks.
[0402] 151. The method of any one of embodiments 82-150, wherein the patient is not administered another therapeutic agent for treatment of chronic hand eczema.
[0403] 152. The method of any one of embodiments 82-150, wherein administration of the acidified aqueous formulation does not cause a burn at the site of administration.
[0404] 153. A method of reducing pain in a human patient having moderate to severe chronic hand eczema, comprising administering to the skin of the human patient in need thereof twice a day an acidified aqueous topical composition comprising 20 mg / g digoxin or a pharmaceutically acceptable salt thereof on a free base basis, wherein the patient has a baseline HESD pain score (weekly mean) of > 4.
[0405] 154. The method of embodiment 153, wherein the patient: is a teenager between 12 and 17 years of age or an adult 18 years of age or older; wherein the patient has hand eczema that has persisted for more than 3 months or has had two or more relapses of hand eczema within the past 12 months.
[0406] 155. The method of any one of embodiments 153-154, wherein the patient has a documented history of inadequate response to topical corticosteroid (TCS) treatment, or TCS is documented as medically inadvisable for the patient for other reasons (e.g., due to major side effects or safety risks).
[0407] 156. The method of any one of embodiments 153-155, wherein dicitabine is dissolved in the aqueous phase of the acidified aqueous topical formulation.
[0408] 157. The method of embodiment 156, wherein the acidified aqueous topical formulation has a pH of less than about 4.6 or less than about 4.4.
[0409] 158. The method of embodiment 157, wherein the acidified aqueous topical formulation has a pH of about 3.8 to about 4.6.
[0410] 159. The method of embodiment 158, wherein the aqueous topical formulation has a pH of about 4.3 or less.
[0411] 160. The method of embodiment 159, wherein the aqueous topical formulation has a pH of about 4.2 or less.
[0412] 161. The method of any one of embodiments 156-160, wherein the aqueous topical formulation comprises a lipid matrix.
[0413] 162. The method of any one of embodiments 153-161, wherein at week 8, the patient achieves a reduction of >4 points in HEDS pain score (weekly mean) from baseline.
[0414] 163. The method of embodiment 162, wherein at week 4, the patient achieves a reduction of >4 points in HEDS pain score (weekly mean) from baseline.
[0415] 164. The method of embodiment 163, wherein at week 2, the patient achieves a reduction of >4 points in HEDS pain score (weekly mean) from baseline.
[0416] 165. The method of embodiment 164, wherein at week 1, the patient achieves a reduction of >4 points in HEDS pain score (weekly mean) from baseline.
[0417] 166. The method of embodiment 165, at day 6, the patient achieves a reduction of >4 points in HEDS pain score (weekly mean) from baseline.
[0418] 167. The method of embodiment 166, wherein at day 5, the patient achieves a reduction of >4 points in HEDS pain score (weekly mean) from baseline.
[0419] 168. The method of embodiment 167, wherein at day 4, the patient achieves a reduction of >4 points in HEDS pain score (weekly mean) from baseline.
[0420] 169. The method of embodiment 168, wherein the patient achieves a reduction of >4 points in HEDS pain score (weekly mean) from baseline at day 3.
[0421] 170. The method of embodiment 169, wherein the patient achieves a reduction of >4 points in HEDS pain score (weekly mean) from baseline at day 2 or within 36 hours.
[0422] 171. The method of embodiment 170, wherein the patient achieves a reduction of >4 points in HEDS pain score (weekly mean) from baseline at day 1 or within 24 hours.
[0423] 172. The method of embodiment 153, wherein the patient achieves rapid reduction in pain.
[0424] 173. The method of any one of embodiments 153-172, wherein the patient achieves a statistically significant reduction in HEDS pain score from baseline at day 1 or within 24 hours compared to a patient administered a placebo.
[0425] 174. The method of any one of embodiments 153-172, wherein the patient achieves a reduction of 1 point in HEDS pain score from baseline at day 1 or within 24 hours.
[0426] 175. The method of any one of embodiments 153-172, wherein the patient achieves a statistically significant reduction in HEDS pain score from baseline at day 2 or within 36 hours compared to a patient administered a placebo.
[0427] 176. The method of any one of embodiments 153-172, wherein the patient achieves a reduction of 2 points in HEDS pain score from baseline at day 2 or within 36 hours.
[0428] 177. The method of any one of embodiments 153-172, wherein the patient achieves a reduction of 3 points in HEDS pain score from baseline at week 8.
[0429] 178. The method of any one of embodiments 153-172, wherein the patient achieves a reduction of 3 points in HEDS pain score from baseline at week 4.
[0430] 179. The method of any one of embodiments 153-172, wherein the patient achieves a reduction of 3 points in HEDS pain score from baseline at week 2.
[0431] 180. The method of any one of embodiments 153-172, wherein the patient achieves a reduction of 3 points in HEDS pain score from baseline at week 1.
[0432] 181. The method of any one of embodiments 153-172, wherein at week 8, the patient achieves a 4-point reduction in HEDS pain score from baseline.
[0433] 182. The method of any one of embodiments 153-172, wherein at week 4, the patient achieves a 4-point reduction in HEDS pain score from baseline.
[0434] 183. The method of any one of embodiments 153-182, wherein the patient achieves a significant improvement in IGA-CHE score from baseline compared to placebo.
[0435] 184. The method of any one of embodiments 153-182, wherein at week 8, the patient achieves an IGA-CHE score of 0 (cleared) or 1 (almost cleared) and an improvement of >2 steps from baseline.
[0436] 185. The method of embodiment 184, wherein at week 4, the patient achieves an IGA-CHE score of 0 (cleared) or 1 (almost cleared) and an improvement of >2 steps from baseline.
[0437] 186. The method of embodiment 184, wherein at week 2, the patient achieves an IGA-CHE score of 0 (cleared) or 1 (almost cleared) and an improvement of >2 steps from baseline.
[0438] 187. The method of embodiment 184, wherein at week 1, the patient achieves an IGA-CHE score of 0 (cleared) or 1 (almost cleared) and an improvement of >2 steps from baseline.
[0439] 188. The method of embodiment 184, wherein at day 5 or 6, the patient achieves an IGA-CHE score of 0 (cleared) or 1 (almost cleared) and an improvement of >2 steps from baseline.
[0440] 189. The method of embodiment 184, wherein at day 4, the patient achieves an IGA-CHE score of 0 (cleared) or 1 (almost cleared) and an improvement of >2 steps from baseline.
[0441] 190. The method of embodiment 184, wherein at day 3, the patient achieves an IGA-CHE score of 0 (cleared) or 1 (almost cleared) and an improvement of >2 steps from baseline.
[0442] 191. The method of embodiment 184, wherein at day 1 or within 24 hours, the patient achieves an IGA-CHE score of 0 (cleared) or 1 (almost cleared) and an improvement of >2 steps from baseline.
[0443] 192. The method of embodiment 184, wherein the patient achieves an IGA-CHE score of 0 (cleared) or 1 (nearly cleared) and an improvement of >2 steps from baseline at Day 2 or within 36 hours.
[0444] 193. The method of any one of embodiments 153-192, wherein the patient achieves at least a 90% improvement in HECSI score from baseline at Week 16.
[0445] 194. The method of embodiment 193, wherein the patient achieves at least a 90% improvement in HECSI score from baseline at Week 8.
[0446] 195. The method of embodiment 193, wherein the patient achieves at least a 90% improvement in HECSI score from baseline at Week 4.
[0447] 196. The method of embodiment 193, wherein the patient achieves at least a 90% improvement in HECSI score from baseline at Week 2.
[0448] 197. The method of embodiment 193, wherein the patient achieves at least a 90% improvement in HECSI score from baseline at Week 1.
[0449] 198. The method of embodiment 193, wherein the patient achieves at least a 90% improvement in HECSI score from baseline at Day 6.
[0450] 199. The method of embodiment 193, wherein the patient achieves at least a 90% improvement in HECSI score from baseline at Day 5.
[0451] 200. The method of embodiment 193, wherein the patient achieves at least a 90% improvement in HECSI score from baseline at Day 4.
[0452] 201. The method of embodiment 193, wherein the patient achieves at least a 90% improvement in HECSI score from baseline at Day 3.
[0453] 202. The method of embodiment 193, wherein the patient achieves at least a 90% improvement in HECSI score from baseline at Day 2 or within 36 hours.
[0454] 203. The method of embodiment 193, wherein the patient achieves at least a 90% improvement in HECSI score from baseline at Day 1 or within 24 hours.
[0455] 204. The method of any one of embodiments 153-203, wherein at week 16, the patient achieves at least a 75% improvement in HECSI score from baseline.
[0456] 205. The method of embodiment 204, wherein at week 8, the patient achieves at least a 75% improvement in HECSI score from baseline.
[0457] 206. The method of embodiment 204, wherein at week 4, the patient achieves at least a 75% improvement in HECSI score from baseline.
[0458] 207. The method of embodiment 204, wherein at week 2, the patient achieves at least a 75% improvement in HECSI score from baseline.
[0459] 208. The method of embodiment 204, wherein at week 1, the patient achieves at least a 75% improvement in HECSI score from baseline.
[0460] 209. The method of embodiment 204, wherein at day 6, the patient achieves at least a 75% improvement in HECSI score from baseline.
[0461] 210. The method of embodiment 204, wherein at day 5, the patient achieves at least a 75% improvement in HECSI score from baseline.
[0462] 211. The method of embodiment 204, wherein at day 4, the patient achieves at least a 75% improvement in HECSI score from baseline.
[0463] 213. The method of embodiment 204, wherein at day 3, the patient achieves at least a 75% improvement in HECSI score from baseline.
[0464] 214. The method of embodiment 204, wherein at day 2 or within 36 hours, the patient achieves at least a 75% improvement in HECSI score from baseline.
[0465] 215. The method of embodiment 204, wherein at day 1 or within 24 hours, the patient achieves at least a 75% improvement in HECSI score from baseline.
[0466] 216. The method of any one of embodiments 153-215, wherein treatment is continued until the patient achieves clearance or near-clearance of skin.
[0467] 217. The method of any one of embodiments 82-146, wherein administration is for at least 2 weeks.
[0468] 218. The method of embodiment 217, wherein the administration is for at least 4 weeks.
[0469] 219. The method of embodiment 217, wherein the administration is for at least 8 weeks.
[0470] 220. The method of embodiment 217, wherein the administration is for at least 12 weeks.
[0471] 221. The method of any one of embodiments 153-220, wherein the patient is not administered another therapeutic agent for the treatment of chronic hand eczema.
[0472] 222. The method of any one of embodiments 153-220, wherein administration of the acidified aqueous formulation does not cause a burn at the site of administration.
[0473] 223. A method of treating moderate to severe chronic hand eczema in a human patient, comprising administering to the skin of the human patient in need thereof an acidified aqueous topical composition comprising 20 mg / g digoxin or a pharmaceutically acceptable salt thereof on a free base basis twice a day, wherein the administration is for at least 12 weeks, wherein at week 12 the patient achieves an IGA-CHE score of 0 (cleared) or 1 (almost cleared) and an improvement of >2 steps relative to baseline, and wherein the patient has a baseline HESD pruritus score (weekly mean) of >4 and the patient achieves a reduction of >4 points in the HEDS pruritus score (weekly mean) relative to baseline at week 12.
[0474] 224. The method of embodiment 223, wherein the patient is an adult 18 years of age or older, and wherein the patient has hand eczema that persists for more than 3 months or that has recurred two or more times in the past 12 months.
[0475] 225. A method of treating moderate to severe chronic hand eczema in a human patient, comprising administering to the skin of the human patient in need thereof an acidified aqueous topical composition comprising 20 mg / g digoxin or a pharmaceutically acceptable salt thereof on a free base basis twice a day, wherein the administration is for at least 8 weeks, wherein at week 8 the patient achieves an IGA-CHE score of 0 (cleared) or 1 (almost cleared) and an improvement of >2 steps relative to baseline, and wherein the patient has a baseline HESD pruritus score (weekly mean) of >4 and the patient achieves a reduction of >4 points in the HEDS pruritus score (weekly mean) relative to baseline at week 8.
[0476] 226. The method of embodiment 224, wherein the patient is an adult 18 years of age or older, and wherein the patient has hand eczema that persists for more than 3 months or that has recurred two or more times in the past 12 months.
[0477] 227. A method of treating moderate to severe chronic hand eczema in a human patient comprising administering to the skin of the human patient in need thereof an acidified aqueous topical composition comprising 20 mg / g of digoxin based on free base or a pharmaceutically acceptable salt thereof twice a day, wherein the administration is maintained for at least 6 weeks, wherein at week 6 the patient achieves an IGA-CHE score of 0 (cleared) or 1 (almost cleared) and an improvement of >2 steps relative to baseline, and wherein the patient has a baseline HESD pruritus score (weekly mean) of >4 and the patient achieves a reduction of >4 points in HEDS pruritus score (weekly mean) relative to baseline at week 6.
[0478] 228. The method of embodiment 224, wherein the patient is an adult 18 years of age or older, and wherein the patient has hand eczema that persists for more than 3 months or hand eczema that has recurred two or more times in the past 12 months.
[0479] 229. A method of treating moderate chronic hand eczema in a human patient comprising administering to the skin of the human patient in need thereof a topical formulation comprising 20 mg / g of digoxin based on free base or a pharmaceutically acceptable salt thereof twice a day.
[0480] 230. A method of treating severe chronic hand eczema in a human patient comprising administering to the skin of the human patient in need thereof a topical formulation comprising 20 mg / g of digoxin based on free base or a pharmaceutically acceptable salt thereof twice a day.
[0481] 231. The method of any one of embodiments 229-230, wherein the patient has a baseline HESD pruritus score (weekly mean) of >4.
[0482] 232. The method of any one of embodiments 229-231, wherein the patient has an IGA-CHE score of 3 or 4.
[0483] 233. The method of any one of embodiments 229-232, wherein the patient has a documented history of inadequate response to topical corticosteroid (TCS) therapy, or TCS is documented as medically inadvisable for the patient for other reasons (e.g., due to major side effects or safety risks).
[0484] 234. The method of embodiment 233, wherein the patient has a documented history of inadequate response to topical corticosteroid (TCS) therapy.
[0485] 235. The method of embodiment 233, wherein topical corticosteroid (TCS) is documented as medically inadvisable for the patient.
[0486] 236. The method of any one of embodiments 229-235, wherein the patient is an adult 18 years of age or older.
[0487] 237. The method of embodiments 229-235, wherein the patient is a teenager 12-17 years of age.
[0488] 238. The method of any one of embodiments 229-237, wherein the topical formulation is administered for at least 2 weeks.
[0489] 239. The method of embodiment 238, wherein the topical formulation is administered for at least 4 weeks.
[0490] 240. The method of embodiment 239, wherein the topical formulation is administered for at least 8 weeks.
[0491] 241. The method of embodiment 240, wherein the topical formulation is administered for at least 12 weeks.
[0492] 242. The method of embodiment 241, wherein the topical formulation is administered for at least 16 weeks or more.
[0493] 243. The method of any one of embodiments 229-242, wherein at week 8, the patient achieves an IGA-CHE score of 0 (cleared) or 1 (almost cleared) and an improvement of >2 steps from baseline.
[0494] 244. The method of any one of embodiments 229-242, wherein at week 6, the patient achieves an IGA-CHE score of 0 (cleared) or 1 (almost cleared) and an improvement of >2 steps from baseline.
[0495] 245. The method of any one of embodiments 229-242, wherein at week 4, the patient achieves an IGA-CHE score of 0 (cleared) or 1 (almost cleared) and an improvement of >2 steps from baseline.
[0496] 246. The method of any one of embodiments 229-242, wherein at week 2, the patient achieves an IGA-CHE score of 0 (cleared) or 1 (almost cleared) and an improvement of >2 steps from baseline.
[0497] 247. The method of any one of embodiments 229-242, wherein the patient has a baseline HESD pruritus score (weekly mean) of >4 and the patient achieves a reduction of >4 points in HEDS pruritus score (weekly mean) from baseline at Week 8, and wherein the patient achieves an IGA-CHE score of 0 (cleared) or 1 (almost cleared) and an improvement of >2 steps from baseline at Week 8.
[0498] 248. The method of any one of embodiments 229-242, wherein the patient has a baseline HESD pruritus score (weekly mean) of >4 and the patient achieves a reduction of >4 points in HEDS pruritus score (weekly mean) from baseline at Week 6, and wherein the patient achieves an IGA-CHE score of 0 (cleared) or 1 (almost cleared) and an improvement of >2 steps from baseline at Week 6.
[0499] 249. The method of any one of embodiments 229-242, wherein the patient has a baseline HESD pruritus score (weekly mean) of >4 and wherein the patient achieves a reduction of >4 points in HEDS pruritus score (weekly mean) from baseline at Week 4, and wherein the patient achieves an IGA-CHE score of 0 (cleared) or 1 (almost cleared) and an improvement of >2 steps from baseline at Week 4.
[0500] 250. The method of any one of embodiments 229-242, wherein the patient has a baseline HESD pruritus score (weekly mean) of >4 and the patient achieves a reduction of >4 points in HEDS pruritus score (weekly mean) from baseline at Week 2, and wherein the patient achieves an IGA-CHE score of 0 (cleared) or 1 (almost cleared) and an improvement of >2 steps from baseline at Week 2.
[0501] 251. The method of any one of embodiments 229-242, wherein the patient has a baseline HESD pruritus score (weekly mean) of >4 and the patient achieves a reduction of >4 points in HEDS pruritus score (weekly mean) from baseline at Week 1, and wherein the patient achieves an IGA-CHE score of 0 (cleared) or 1 (almost cleared) and an improvement of >2 steps from baseline at Week 1.
[0502] 252. The method of any one of embodiments 229-242, wherein the patient has a baseline HESD pain score (weekly mean) of >4 and the patient achieves a reduction of >4 points in HEDS pain score (weekly mean) from baseline at Week 8, and wherein the patient achieves an IGA-CHE score of 0 (cleared) or 1 (almost cleared) and an improvement of >2 steps from baseline at Week 8.
[0503] 253. The method of any one of embodiments 229-242, wherein the patient has a baseline HESD pain score (weekly mean) of >4, and the patient achieves a reduction of >4 points in HEDS pain score (weekly mean) from baseline at Week 6, and wherein the patient achieves an IGA-CHE score of 0 (cleared) or 1 (almost cleared) and an improvement of >2 steps from baseline at Week 6.
[0504] 254. The method of any one of embodiments 229-242, wherein the patient has a baseline HESD pain score (weekly mean) of >4, and wherein the patient achieves a reduction of >4 points in HEDS pain score (weekly mean) from baseline at Week 4, and wherein the patient achieves an IGA-CHE score of 0 (cleared) or 1 (almost cleared) and an improvement of >2 steps from baseline at Week 4.
[0505] 255. The method of any one of embodiments 229-242, wherein the patient has a baseline HESD pain score (weekly mean) of >4, and the patient achieves a reduction of >4 points in HEDS pain score (weekly mean) from baseline at Week 2, and wherein the patient achieves an IGA-CHE score of 0 (cleared) or 1 (almost cleared) and an improvement of >2 steps from baseline at Week 2.
[0506] 256. The method of any one of embodiments 229-242, wherein the patient has a baseline HESD pain score (weekly mean) of >4, and the patient achieves a reduction of >4 points in HEDS pain score (weekly mean) from baseline at Week 1, and wherein the patient achieves an IGA-CHE score of 0 (cleared) or 1 (almost cleared) and an improvement of >2 steps from baseline at Week 1.
[0507] 257. The method of any one of embodiments 229-242, wherein the patient achieves an IGA-CHE score of 0 (cleared) or 1 (almost cleared) and an improvement of >2 steps from baseline at Week 8, and achieves at least a 90% improvement in HECSI score from baseline at Week 8.
[0508] 258. The method of any one of embodiments 229-242, wherein the patient achieves an IGA-CHE score of 0 (cleared) or 1 (almost cleared) and an improvement of >2 steps from baseline at Week 6, and achieves at least a 90% improvement in HECSI score from baseline at Week 6.
[0509] 259. The method of any one of embodiments 229-242, wherein the patient achieves an IGA-CHE score of 0 (cleared) or 1 (nearly cleared) and an improvement of >2 steps from baseline at Week 4 and achieves at least a 90% improvement in HECSI score from baseline at Week 4.
[0510] 260. The method of any one of embodiments 229-242, wherein the patient achieves an IGA-CHE score of 0 (cleared) or 1 (nearly cleared) and an improvement of >2 steps from baseline at Week 2 and achieves at least a 90% improvement in HECSI score from baseline at Week 2.
[0511] 261. The method of any one of embodiments 229-242, wherein the patient achieves an IGA-CHE score of 0 (cleared) or 1 (nearly cleared) and an improvement of >2 steps from baseline at Week 1 and achieves at least a 90% improvement in HECSI score from baseline at Week 1.
[0512] 262. The method of any one of embodiments 229-242, wherein the patient achieves an IGA-CHE score of 0 (cleared) or 1 (nearly cleared) and an improvement of >2 steps from baseline at Week 8 and achieves at least a 75% improvement in HECSI score from baseline at Week 8.
[0513] 263. The method of any one of embodiments 229-242, wherein the patient achieves an IGA-CHE score of 0 (cleared) or 1 (nearly cleared) and an improvement of >2 steps from baseline at Week 6 and achieves at least a 90% improvement in HECSI score from baseline at Week 6.
[0514] 264. The method of any one of embodiments 229-242, wherein the patient achieves an IGA-CHE score of 0 (cleared) or 1 (nearly cleared) and an improvement of >2 steps from baseline at Week 4 and achieves at least a 75% improvement in HECSI score from baseline at Week 4.
[0515] 265. The method of any one of embodiments 229-242, wherein the patient achieves an IGA-CHE score of 0 (cleared) or 1 (nearly cleared) and an improvement of >2 steps from baseline at Week 2 and achieves at least a 75% improvement in HECSI score from baseline at Week 2.
[0516] 266. The method of any one of embodiments 229-242, wherein the patient achieves an IGA-CHE score of 0 (cleared) or 1 (almost cleared) and an improvement of >2 steps from baseline at Week 1 and achieves an improvement in HECSI score of at least 75% from baseline at Week 1.
[0517] 267. The method of any one of embodiments 229-242, wherein the patient has a baseline HESD pruritus score (weekly mean) of >4 and the patient achieves a reduction in HEDS pruritus score (weekly mean) of >4 from baseline, an IGA-CHE score of 0 (cleared) or 1 (almost cleared) and an improvement of >2 steps from baseline, and an improvement in HECSI score of at least 75% from baseline at Week 8.
[0518] 268. The method of any one of embodiments 229-242, wherein the patient has a baseline HESD pruritus score (weekly mean) of >4 and the patient achieves a reduction in HEDS pruritus score (weekly mean) of >4 from baseline, an IGA-CHE score of 0 (cleared) or 1 (almost cleared) and an improvement of >2 steps from baseline, and an improvement in HECSI score of at least 75% from baseline at Week 6.
[0519] 269. The method of any one of embodiments 229-242, wherein the patient has a baseline HESD pruritus score (weekly mean) of >4 and the patient achieves a reduction in HEDS pruritus score (weekly mean) of >4 from baseline, an IGA-CHE score of 0 (cleared) or 1 (almost cleared) and an improvement of >2 steps from baseline, and an improvement in HECSI score of at least 75% from baseline at Week 4.
[0520] 270. The method of any one of embodiments 229-242, wherein the patient has a baseline HESD pruritus score (weekly mean) of >4 and the patient achieves a reduction in HEDS pruritus score (weekly mean) of >4 from baseline, an IGA-CHE score of 0 (cleared) or 1 (almost cleared) and an improvement of >2 steps from baseline, and an improvement in HECSI score of at least 75% from baseline at Week 2.
[0521] 271. The method of any one of embodiments 229-242, wherein the patient has a baseline HESD pruritus score (weekly mean) of >4 and the patient achieves a reduction in HEDS pruritus score (weekly mean) of >4 from baseline, an IGA-CHE score of 0 (cleared) or 1 (almost cleared) and an improvement of >2 steps from baseline, and an improvement in HECSI score of at least 75% from baseline at Week 1.
[0522] 272. The method of any one of embodiments 229-242, wherein the patient has a baseline HESD Pruritus Score (weekly mean) of >4 and the patient achieves a reduction of >4 points in the HEDS Pruritus Score (weekly mean) from baseline at Week 8, an IGA-CHE score of 0 (cleared) or 1 (almost cleared) with an improvement of >2 steps from baseline, and at least 90% improvement in the HECSI score from baseline at Week 8.
[0523] 273. The method of any one of embodiments 229-242, wherein the patient has a baseline HESD Pruritus Score (weekly mean) of >4 and the patient achieves a reduction of >4 points in the HEDS Pruritus Score (weekly mean) from baseline at Week 8, an IGA-CHE score of 0 (cleared) or 1 (almost cleared) with an improvement of >2 steps from baseline, and at least 90% improvement in the HECSI score from baseline at Week 6.
[0524] 274. The method of any one of embodiments 229-242, wherein the patient has a baseline HESD Pruritus Score (weekly mean) of >4 and the patient achieves a reduction of >4 points in the HEDS Pruritus Score (weekly mean) from baseline at Week 8, an IGA-CHE score of 0 (cleared) or 1 (almost cleared) with an improvement of >2 steps from baseline, and at least 90% improvement in the HECSI score from baseline at Week 4.
[0525] 275. The method of any one of embodiments 229-242, wherein the patient has a baseline HESD Pruritus Score (weekly mean) of >4 and the patient achieves a reduction of >4 points in the HEDS Pruritus Score (weekly mean) from baseline at Week 8, an IGA-CHE score of 0 (cleared) or 1 (almost cleared) with an improvement of >2 steps from baseline, and at least 90% improvement in the HECSI score from baseline at Week 2.
[0526] 276. The method of any one of embodiments 229-242, wherein the patient has a baseline HESD Pruritus Score (weekly mean) of >4 and the patient achieves a reduction of >4 points in the HEDS Pruritus Score (weekly mean) from baseline at Week 8, an IGA-CHE score of 0 (cleared) or 1 (almost cleared) with an improvement of >2 steps from baseline, and at least 90% improvement in the HECSI score from baseline at Week 1.
[0527] 277. The method of any one of embodiments 229-242, wherein the patient has a baseline HESD Eczema Area Scoring Index (EASI) score of > 25 and the patient achieves a reduction from baseline of > 25 in HESD EASI score at Week 8, an IGA-CHE score of 0 (cleared) or 1 (almost cleared) and an improvement of > 2 steps from baseline, and an improvement of at least 75% from baseline in HECSI score.
[0528] 278. The method of any one of embodiments 229-242, wherein the patient has a baseline HESD Eczema Area Scoring Index (EASI) score of > 25 and the patient achieves a reduction from baseline of > 25 in HESD EASI score at Week 6, an IGA-CHE score of 0 (cleared) or 1 (almost cleared) and an improvement of > 2 steps from baseline, and an improvement of at least 75% from baseline in HECSI score.
[0529] 279. The method of any one of embodiments 229-242, wherein the patient has a baseline HESD Eczema Area Scoring Index (EASI) score of > 25 and the patient achieves a reduction from baseline of > 25 in HESD EASI score at Week 4, an IGA-CHE score of 0 (cleared) or 1 (almost cleared) and an improvement of > 2 steps from baseline, and an improvement of at least 75% from baseline in HECSI score.
[0530] 280. The method of any one of embodiments 229-242, wherein the patient has a baseline HESD Eczema Area Scoring Index (EASI) score of > 25 and the patient achieves a reduction from baseline of > 25 in HESD EASI score at Week 2, an IGA-CHE score of 0 (cleared) or 1 (almost cleared) and an improvement of > 2 steps from baseline, and an improvement of at least 75% from baseline in HECSI score.
[0531] 281. The method of any one of embodiments 229-242, wherein the patient has a baseline HESD Eczema Area Scoring Index (EASI) score of > 25 and the patient achieves a reduction from baseline of > 25 in HESD EASI score at Week 1, an IGA-CHE score of 0 (cleared) or 1 (almost cleared) and an improvement of > 2 steps from baseline, and an improvement of at least 75% from baseline in HECSI score.
[0532] 282. The method of any one of embodiments 229-242, wherein the patient has a baseline HESD Eczema Area Scoring Index (EASI) score of > 25 and the patient achieves a reduction of > 50% from baseline in HESD EASI score at Week 8, an IGA-CHE score of 0 (cleared) or 1 (almost cleared) and an improvement of > 2 steps from baseline, and achieves at least a 90% improvement from baseline in HECSI score at Week 8.
[0533] 283. The method of any one of embodiments 229-242, wherein the patient has a baseline HESD Eczema Area Scoring Index (EASI) score of > 25 and the patient achieves a reduction of > 50% from baseline in HESD EASI score at Week 8, an IGA-CHE score of 0 (cleared) or 1 (almost cleared) and an improvement of > 2 steps from baseline, and achieves at least a 90% improvement from baseline in HECSI score at Week 6.
[0534] 284. The method of any one of embodiments 229-242, wherein the patient has a baseline HESD Eczema Area Scoring Index (EASI) score of > 25 and the patient achieves a reduction of > 50% from baseline in HESD EASI score at Week 8, an IGA-CHE score of 0 (cleared) or 1 (almost cleared) and an improvement of > 2 steps from baseline, and achieves at least a 90% improvement from baseline in HECSI score at Week 4.
[0535] 285. The method of any one of embodiments 229-242, wherein the patient has a baseline HESD Eczema Area Scoring Index (EASI) score of > 25 and the patient achieves a reduction of > 50% from baseline in HESD EASI score at Week 8, an IGA-CHE score of 0 (cleared) or 1 (almost cleared) and an improvement of > 2 steps from baseline, and achieves at least a 90% improvement from baseline in HECSI score at Week 2.
[0536] 286. The method of any one of embodiments 229-242, wherein the patient has a baseline HESD Eczema Area Scoring Index (EASI) score of > 25 and the patient achieves a reduction of > 50% from baseline in HESD EASI score at Week 8, an IGA-CHE score of 0 (cleared) or 1 (almost cleared) and an improvement of > 2 steps from baseline, and achieves at least a 90% improvement from baseline in HECSI score at Week 1.
[0537] 287. The method of any one of embodiments 229-286, wherein the patient: is a teenager between 12 and 17 years of age or an adult 18 years of age or older; wherein the patient has hand eczema that has persisted for more than 3 months or has had two or more relapses of hand eczema within the past 12 months.
[0538] 288. The method of any one of embodiments 229-286, wherein the patient has a documented history of inadequate response to topical corticosteroid (TCS) therapy, or the TCS is documented as medically inadvisable for the patient for other reasons (e.g., due to major side effects or safety risks).
[0539] 289. The method of any one of embodiments 229-286, wherein the topical formulation is an aqueous cream.
[0540] 290. The method of embodiment 289, wherein the digoxin is dissolved in the aqueous phase of the aqueous cream.
[0541] 291. The method of embodiment 290, wherein the aqueous cream is acidified and has a pH of less than about 4.6.
[0542] 292. The method of embodiment 291, wherein the aqueous cream has a pH of about 3.8 to about 4.6.
[0543] 293. The method of embodiment 292, wherein the aqueous topical formulation has a pH of about 4.3 or less.
[0544] 294. The method of embodiment 293, wherein the aqueous topical formulation has a pH of about 4.2 or less.
[0545] 295. The method of any one of embodiments 291-294, wherein the aqueous cream comprises a lipid base.
[0546] 296. The method of embodiment 295, wherein the lipid base is liquid paraffin.
[0547] 297. The method of any one of embodiments 1-296, wherein the acidified aqueous topical composition or aqueous cream comprises a surfactant, emulsifier, or stabilizer.
[0548] 298. The method according to claim 297, wherein the surfactant, emulsifier, or stabilizer is selected from one or more of cetearyl alcohol and polyoxyl cetyl ether.
[0549] 299. The method of embodiment 298, wherein the surfactant, emulsifier, or stabilizer is selected from at least about 30 mg / g to about 80 mg / g cetearyl alcohol.
[0550] 300. The method according to any one of embodiments 298-299, the surfactant, emulsifier, or stabilizing agent is selected from at least about 12 mg / g to about 22 mg / g polyoxyl cetyl stearate.
[0551] 301. The method according to embodiment 296, wherein the aqueous cream or acidified aqueous topical composition comprises liquid paraffin present in an amount of about 60 mg / g to about 140 mg / g, cetylstearyl alcohol in an amount of about 60 mg / g to about 90 mg / g, and polyoxyl cetyl stearate present in an amount of about 14 mg / g to about 22 mg / g.
[0552] 302. The method according to embodiment 301, wherein the aqueous cream or acidified aqueous topical composition comprises liquid paraffin in an amount of about 100 mg / g, cetylstearyl alcohol in an amount of about 72 mg / g, and polyoxyl cetyl stearate in an amount of about 18 mg / g.
[0553] 303. The method according to any one of embodiments 296-302, wherein the aqueous cream or acidified aqueous topical composition comprises a buffering agent or pH adjusting agent.
[0554] 304. The method of embodiment 303, wherein the buffering agent is a phosphate, citrate, or acetate buffering agent.
[0555] 305. The method of embodiment 304, wherein the aqueous cream or acidified aqueous topical composition comprises citric acid monohydrate in an amount of about 0.5 mg / g to about 4 mg / g.
[0556] 306. The method according to embodiment 305, wherein the aqueous cream or acidified aqueous topical composition comprises sodium citrate dihydrate in an amount of 0 mg / g to about 1 mg / g.
[0557] 307. The method according to any one of embodiments 296-306, wherein the aqueous cream or acidified aqueous topical composition comprises benzyl alcohol in an amount of about 7 mg / g to about 13 mg / g.
[0558] 308. The method according to embodiment 307, wherein the amount of benzyl alcohol is about 9 mg / g to about 11 mg / g.
[0559] 309. The method according to any one of embodiments 296-308, wherein the aqueous cream or acidified aqueous topical composition comprises butylated hydroxyanisole in an amount of about 0.05 mg / g to about 0.3 mg / g.
[0560] 310. The method according to embodiment 309, wherein the aqueous cream or acidified aqueous topical composition comprises disodium ethylenediaminetetraacetate in an amount of about 0.05 mg / g to about 1.5 mg / g.
[0561] 311. The method according to any one of embodiments 296-308, wherein the aqueous cream or acidified aqueous topical composition comprises hydrochloric acid in an amount of 0.1 mg / g to about 25 mg / g.
[0562] 312. The method according to embodiment 311, wherein the aqueous cream or acidified aqueous topical composition comprises hydrochloric acid in an amount of 10 mg / g to about 20 mg / g.
[0563] 313. The method according to any one of embodiments 296-308, wherein the aqueous cream or acidified aqueous topical composition comprises purified water present in an amount of about 500 mg / g to about 900 mg / g.
[0564] 314. The method according to any one of embodiments 296-313, wherein the aqueous cream or acidified aqueous topical composition comprises dinaciclib 20 mg / g; liquid paraffin, cetylstearyl alcohol, polyoxyl cetylstearyl ether, benzyl alcohol, citric acid, butylhydroxyanisole, disodium ethylenediaminetetraacetate, hydrochloric acid, and purified water.
[0565] 315. The method according to embodiment 314, wherein the aqueous cream or acidified aqueous topical composition comprises dinaciclib 20 mg / g; liquid paraffin, 100 mg / g; cetylstearyl alcohol, 72 mg / g; polyoxyl cetylstearyl ether, 18 mg / g; benzyl alcohol, 10 mg / g; citric acid monohydrate, 1 mg / g; butylhydroxyanisole, 0.2 mg / g; disodium ethylenediaminetetraacetate, 0.6 mg / g; 3M hydrochloric acid, 17.7 mg / g; and purified water, 760 mg / g.
[0566] 316. The method according to any one of embodiments 296-315, wherein the aqueous cream or acidified aqueous topical composition has about the same or improved skin penetration as compared to a 30 mg ointment comprising 30 mg / g dinaciclib, 820 mg / g white soft paraffin, 50 mg / g hard paraffin, and 100 mg / g squalene, as measured in an open flow microperfusion test in pigs.
[0567] 317. The method of any one of embodiments 1-316, wherein treatment of the affected area twice daily is restarted as needed in case of recurrence of (flare-up) signs and symptoms.
[0568] 318. The method of any one of embodiments 1-317, wherein the applying to the skin of the human patient is applying to the hands and wrists of the human patient.
[0569] 319. The acidified aqueous topical composition according to any one of embodiments 1-318, comprising 20 mg / g of deguelin or a pharmaceutically acceptable salt thereof on a free base basis, for use in a method according to any one of embodiments 1-318.
[0570] 320. Use of deguelin for the manufacture of an acidified aqueous topical composition according to any one of embodiments 1-318, comprising 20 mg / g of deguelin or a pharmaceutically acceptable salt thereof on a free base basis, for use in a method according to any one of claims 1-318.
[0571] Example 1
[0572] Delta 1 and Delta 2 are two phase 3 clinical trials designed to confirm the efficacy of deguelin cream 20 mg / g twice daily compared to a cream vehicle and to assess safety in adult subjects with moderate to severe chronic hand eczema for a treatment period of 16 weeks (Delta 1).
[0573] The primary objective primary endpoint is IGA-CHE TS at Week 16.
[0574] The primary objective secondary endpoints are HECSI-75 at Week 16, HECSI-75 at Week 8, HECSI-90 at Week 16, IGA-CHE TS at Week 8, IGA-CHE TS at Week 4, and percent change from baseline in HECSI score at Week 16.
[0575] Other endpoints are disclosed in Tables 7 and 8 above.
[0576] For DELTA 1, 487 patients from 6 countries (Canada [n=97], France [n=81], Germany [n=135], Italy [n=45], Poland [n=105], and the United Kingdom [n=24]) were randomized to receive diclofenac cream (n = 325; 66.7%) and cream vehicle (n = 162; 33.3%). For DELTA 2, 473 patients from 7 countries (Belgium [n=22], Canada [n=97], Denmark [n=22], Germany [n = 147], the Netherlands [n=24], Poland [n=96], and Spain [n=65]) were randomized, of which 314 (66.4%) received diclofenac cream and 159 (33.6%) received cream vehicle. Overall, 487 (DELTA 1) and 472 (DELTA 2) patients were included in the full analysis set and the safety analysis set. A total of 459 (94.3%) and 420 (88.8%) patients completed DELTA 1 and DELTA 2, respectively. Overall, 6.2% (DELTA 1) and 7.0% (DELTA 2) of patients treated with diclofenac cream and 13.0% (DELTA 1) and 23.3% (DELTA 2) of patients in the cream vehicle group discontinued study treatment. For both studies, baseline demographics and patient characteristics were comparable between patients treated with diclofenac cream and patients treated with cream vehicle (Table 11). Overall, 99.4% (DELTA 1) and 98.5% (DELTA 1) of patients had a history of inadequate response to TCS therapy in the recent past (Table 12).
[0577] Baseline Demographics and Characteristics:
[0578] Table 11. Patient demographics and baseline characteristics in DELTA 1 and DELTA 2
[0579]
[0580] Note: Differences in the number of patients assessed for certain assessments are due to missing assessments at baseline for some patients; HESD pruritus, HESD pain, and HESD score range from 0-10; HEIS and HEIS PDAL range from 0-4.
[0581] a At baseline, one patient also had CHE subtype contact urticaria / protein contact dermatitis.
[0582] Table 12. Summary of additional baseline characteristics and prior CHE treatment in DELTA 1 and DELTA 2
[0583]
[0584] Note: Discrepancies in the number of patients evaluated for certain assessments are due to missing assessments at baseline for some patients.
[0585] a The most frequently reported (>2% of patients) included antihistamines, emollients and protectants, and antibiotics. CHE, chronic hand eczema; HEIS, Hand Eczema Impact Scale; N, number of patients in the analysis set; n, number of patients with an observation; PDAL: proximal daily activity limitation; TCI, topical calcineurin inhibitor; TCS, topical corticosteroid.
[0586] Investigational Medicinal Product (IMP)
[0587] The active IMP and placebo IMP were as follows:
[0588]
[0589] Dipegliben cream 20 mg / g contained:
[0590] Dipegliben 20 mg / g; liquid paraffin, 100 mg / g; cetostearyl alcohol, 72 mg / g; polyoxyl 40 cetostearyl ether, 18 mg / g; benzyl alcohol, 10 mg / g; citric acid monohydrate, 1 mg / g; butylated hydroxyanisole, 0.2 mg / g; disodium edetate, 0.6 mg / g; 3M hydrochloric acid, 17.7 mg / g; and purified water, 760 mg / g.
[0591] The cream vehicle contained the same excipients in corresponding amounts.
[0592] Administration of IMP
[0593] The IMP (Dipegliben cream 20 mg / g or cream vehicle) was applied as a topical application twice daily, with an interval of about 12 hours between each application, for 16 weeks.
[0594] Inclusion Criteria:
[0595] Subjects had to meet all of the following criteria to be eligible for participation in the trial:
[0596] 1. Signed and dated informed consent had been obtained prior to any protocol-related procedures being performed.
[0597] 2. Age 18 years or older at the time of screening.
[0598] 3. Diagnosis of CHE, defined as hand eczema lasting more than 3 months or relapsing two or more times in the past 12 months.
[0599] 4. Disease severity is graded as moderate to severe (i.e. IGA-CHE score of 3 or 4) at screening and at baseline according to IGA-CHE.
[0600] 5. HESD Pruritus score (weekly mean) > 4 at baseline. Baseline weekly mean is calculated from daily assessment of pruritus severity during the 7 days immediately preceding the baseline visit (Day -7 to Day -1). Seven days of at least 4 pruritus scores are required to calculate the baseline mean score.
[0601] 6. Subject has a documented history of inadequate response to TCS treatment (at any time within 1 year prior to the screening visit) or TCS is documented as medically inadvisable for the subject for other reasons (e.g. due to major side effects or safety risks).
[0602] • Inadequate response is defined as a documented history of failure to achieve and maintain low disease activity (equivalent to IGA-CHE score < 2) despite regular use of TCS treatment of Class III-IV (strong to very strong) in Europe and Class IV-I (moderate to very high / super high potency) in Canada for at least 28 days or for the duration recommended in the product’s prescribing information, whichever is shorter.
[0603] • Major side effects or safety risks refer to side effects or safety risks that outweigh the potential therapeutic benefit and include physician assessed treatment intolerance, hypersensitivity reactions, and severe skin atrophy.
[0604] 7. Subject adheres to standard non-pharmacological skin care, including avoidance of known and relevant irritants and allergens.
[0605] 8. Women of childbearing potential must use an acceptable method of contraception throughout the trial until the last application of IMP.
[0606] Exclusion Criteria:
[0607] A subject is not eligible for the trial if they meet any of the following criteria:
[0608] 1. Active concurrent skin disease of the hands, e.g. tinea manuum.
[0609] 2. Active AD requiring medical treatment on sites other than the hands and feet.
[0610] 3. Active psoriasis on any site of the body.
[0611] 4. Combination of hyperkeratotic hand eczema with a history of psoriasis on any site of the body.
[0612] 5. Have clinically significant infection on the hands (e.g., pustular hand eczema).
[0613] 6. Have received systemic treatment with immunosuppressive drugs (e.g., methotrexate, cyclosporine, azathioprine), immunomodulatory drugs, retinoids (e.g., alitretinoin), or corticosteroids within 28 days prior to baseline (for allergic conjunctivitis, asthma, or rhinitis, use of topical ocular steroid corresponding to up to 1 mg of prednisolone and inhaled or intranasal steroids is allowed).
[0614] 7. Have used a sunbed, phototherapy (e.g., UVB, UVA1, PUVA), or bleaching bath on the hands within 28 days prior to baseline.
[0615] 8. Have received systemic or topical treatment with a JAK inhibitor (including decernotinib / LEO 124249) either previously or currently.
[0616] 9. Have received treatment with a percutaneously applied immunomodulatory agent (e.g., PDE-4 inhibitor, pimecrolimus, tacrolimus) or TCS on the hands within 14 days prior to baseline.
[0617] 10. Have used systemic antibiotics or percutaneously applied antibiotics on the hands within 14 days prior to baseline.
[0618] 11. Have received other transdermal or percutaneously applied therapy on the hands within 7 days prior to baseline (except use of the subject's own emollient cream).
[0619] 12. Have received percutaneously applied treatment on areas other than the hands within 7 days prior to baseline that could interfere with the clinical trial assessments or cause safety concerns.
[0620] 13. Have received treatment with any marketed biologic therapy or investigational biologic agent (including immunoglobulin, anti-IgE, and dupilumab):
[0621] • Any cell depleting agent, including but not limited to rituximab: within 6 months of baseline, or until lymphocyte counts have returned to normal, whichever is longer.
[0622] • Other biologic agents: within 3 months of baseline or 5 half-lives, whichever is longer.
[0623] 14. Have received treatment with any non-marketed drug substance (i.e., an agent that has not yet been made available for clinical use after registration) within the last 28 days of baseline or 5 half-lives, whichever is longer.
[0624] 15. A clinically significant infection within 28 days prior to baseline that, in the opinion of the Investigator, could compromise the safety of the subject in the trial, interfere with the evaluation of the IMP, or reduce the ability of the subject to participate in the trial.
[0625] A clinically significant infection is defined as:
[0626] • A systemic infection.
[0627] • A severe skin infection requiring parenteral (intravenous or intramuscular injection) antibiotics, antiviral, or antifungal medication.
[0628] 16. Any known history of primary immunodeficiency disease, including a positive HIV virus test at screening, or the subject is determined to be taking antiretroviral medication based on medical history and / or the subject’s oral report.
[0629] 17. Major surgery within 8 weeks prior to screening, or planned inpatient surgery or hospitalization during the trial.
[0630] 18. History of cancer:
[0631] • Subjects with basal cell carcinoma, squamous cell carcinoma of the skin, or cervical carcinoma in situ are eligible to participate in the trial if the following conditions are met: the subject is in remission and completed curative therapy at least 12 months prior to screening.
[0632] • Subjects with other malignancies are eligible to participate in the trial if the following conditions are met: the subject is in remission and completed curative therapy at least 5 years prior to screening.
[0633] 19. Any condition that is unstable and likely to occur:
[0634] • That affects the subject’s safety throughout the trial.
[0635] • That interferes with the subject’s ability to complete the trial.
[0636] Examples include, but are not limited to, cardiovascular disorders, gastrointestinal disorders, liver disorders, kidney disorders, nervous system disorders, musculoskeletal disorders, infectious disorders, endocrine disorders, metabolic disorders, blood disorders, immune system disorders, and psychiatric disorders, and major physical disability.
[0637] 20. Any abnormal finding that is likely to occur:
[0638] • That exposes the subject to risk as a result of participating in the trial.
[0639] • That interferes with the subject’s ability to complete the trial.
[0640] Abnormal findings must be clinically significant and observed during screening. Examples include abnormal findings in physical examination, vital signs, ECG, hematology, clinical chemistry, or urinalysis.
[0641] 21. Seropositive for hepatitis B surface antigen or hepatitis C virus antibodies at screening.
[0642] 22. ALT or AST levels > 2.0 x ULN at screening.
[0643] 23. Known or suspected hypersensitivity to any component of the IMP
[0644] 24. Currently participating in any other interventional clinical trial.
[0645] 25. Previously randomized in this clinical trial.
[0646] 26. Current or recent chronic alcohol or drug abuse, or any other condition judged by the investigator to be associated with poor compliance.
[0647] 27. Employee of the trial site, or any other person directly involved in the planning or conduct of the trial, or immediate family member of such a person.
[0648] 28. Institutionalized subjects.
[0649] Female subjects who are pregnant or lactating.
[0650] Study Overview
[0651] Screening Period (-4 Weeks to Week 0)
[0652] The screening period lasts a minimum of 1 week and a maximum of 4 weeks (i.e., the screening visit is between Week -4 and Week -1). For subjects using a treatment listed as an exclusion criterion, the duration of the screening period depends on the required washout period. Given that the washout period for some of these treatments is 28 days, the screening period can be extended up to 31 days. Only subjects who are deemed able to stop the prohibited treatment during the screening period and who do not experience an intolerable worsening of CHE symptoms are included in the trial.
[0653] At the screening visit, the subject’s eligibility to participate in the trial is checked.
[0654] The subject’s CHE subtype is classified according to standard clinical practice in Canada and Europe.
[0655] Treatment Period (Week 0 to Week 16)
[0656] At baseline (Day 1), subjects were confirmed for eligibility to participate in the trial. Eligible subjects were randomized in a 2: 1 ratio to either diclofenac cream 20 mg / g or cream vehicle.
[0657] The IMP (diclofenac cream 20 mg / g or cream vehicle) was applied twice daily for 16 weeks. The first application of the IMP was performed at the trial site on Day 1 after all baseline assessments were performed. All subsequent IMP applications were performed by the subject at home.
[0658] During the 16-week treatment period, subjects returned to the trial site for efficacy and safety assessments. The last IMP application was performed at home by the subject prior to their visit to the trial site scheduled for Week 16. Efficacy and safety assessments during treatment were performed.
[0659] All eligible subjects who did not permanently discontinue the IMP prior to Week 16 were invited to participate in the LTE trial.
[0660] Follow-up Period (Week 16 to Week 18)
[0661] These subjects who did not participate in the LTE trial were followed up (by telephone, but an on-site visit was possible if needed) approximately 2 weeks after the last IMP application to assess safety. Note that for subjects who permanently discontinued the IMP, the 2-week follow-up period started at the time of the last IMP application.
[0662] Subjects who participated in the LTE trial did not need to complete the follow-up period as the LTE trial continued with safety data collection and safety monitoring.
[0663] Efficacy at Weeks 4, 8, and 16:
[0664] For DELTA 1 and DELTA 2, the primary study endpoint (IGA-CHE score of 0 [cleared] or 1 [almost cleared] with at least a 2-step improvement at Week 16) was achieved in 19.7% (n = 64; DELTA 1) and 29.1% (n = 91; DELTA 2) of patients in the diclofenac cream group and in 9.9% (n = 16; DELTA 1) and 6.9% (n = 11; DELTA 2) of patients in the respective cream vehicle group (p = 0.0001 for DELTA 1 and p = 0.0002 for DELTA 2). Figure 1). The proportion of patients achieving IGH-CHE TS was significantly higher in the diclofenac cream group compared with the vehicle cream group at Week 16 (P < 0.006 for both studies). The proportion of patients achieving IGA-CHE treatment success was higher with diclofenac cream treatment compared with cream vehicle during the 16-week treatment period of DELTA 1 and DELTA 2, with statistically significantly more patients achieving IGA-CHE treatment success with diclofenac cream treatment compared with cream vehicle treatment at Week 4 (P < 0.043) and Week 8 (P < 0.001). Figure 1 ).
[0665] The percentage of patients achieving a reduction of >4 points in HECSI-75 and HECSI-90 scores and DLQI score from baseline to Week 16 was statistically significantly higher in the diclofenac cream groups of DELTA 1 and DELTA 2 compared with the respective cream vehicle groups (P < 0.001; Figure 2A -C).
[0666] The least squares (LS) mean change from baseline to Week 16 in HESD pain score was -3.4 in patients treated with diclofenac cream and -1.8 in patients treated with cream vehicle in the DELTA 1 trial (P < 0.001; Figure 3 ). In the DELTA 2 study, the corresponding LS mean change was -3.3 in the diclofenac cream group and -1.3 in the cream vehicle group (P < 0.001). The proportion of patients achieving a reduction of >4 points in HESD pain score from baseline to Week 16 was statistically significantly higher in patients treated with diclofenac cream compared with patients treated with cream vehicle (DELTA 1 : 49.1%; DELTA 2: 48.6%) in patients with a baseline HESD pain score of >4 points (DELTA 1 : 27.5%; DELTA 2: 22.7%; P < 0.001; Figure 4A -B).
[0667] A similar reduction in HESD pruritus score was observed in DELTA 1, with a LS mean change from baseline to Week 16 of -3.6 in the diclofenac cream group and -1.9 in the cream vehicle group (P < 0.001; Figure 5). In the DELTA 2 study, the corresponding LS mean change from baseline in patients treated with diclofenac cream was -3.4 and in patients treated with cream vehicle was -1.4 (P < 0.001). Thus, in study participants with a baseline HESD pruritus score of >4, the proportion of patients treated with diclofenac cream who achieved a reduction in HESD pruritus score of >4 from baseline to Week 16 was statistically significantly higher than in patients treated with cream vehicle (DELTA 1 : 23.0%; DELTA 2: 19.9%; diclofenac cream vs. cream vehicle: P < 0.001; Figure 4B ) compared to patients treated with cream vehicle (DELTA 1 : 47.2%; DELTA 2: 44.5%). Difference from vehicle: Delta 1 was 22.8% and Delta 2 was 23.6%.
[0668] In DELTA 1 and DELTA 2, patients treated with diclofenac achieved statistically significantly higher LS mean reductions in pain and pruritus scores from baseline to Week 1-4 compared to patients receiving cream vehicle (P < 0.002; Figure 3 and Figure 5 ). Similarly, in patients with a baseline HESD pain and pruritus score of >4, the proportion of patients treated with diclofenac cream who achieved a reduction in HESD pain and pruritus score of >4 from baseline to Week 2-4 was statistically significantly higher than in patients treated with cream vehicle (P < 0.031; Figure 4A -B).
[0669] In patients with a baseline HESD score of >4, the proportion of patients treated with diclofenac cream who achieved a reduction in HESD score of >4 from baseline to Week 16 was statistically significantly higher than in patients treated with cream vehicle (DELTA 1 : 47.2%; DELTA 2: 44.5%) compared to patients treated with cream vehicle (DELTA 1 : 24.4%; DELTA 2: 20.9%; P < 0.001). Difference from vehicle: Delta 1 was 22.8% and Delta 2 was 23.6%.
[0670] Safety:
[0671] In DELTA 1 and DELTA 2, a comparable percentage of patients treated with diclofenac cream and cream vehicle reported AEs (diclofenac cream: 45.2% [DELTA 1] and 45.7% [DELTA 2]; cream vehicle: 50.6% [DELTA 1] and 44.7% [DELTA 2]; Figure 6). Most AEs were mild to moderate and considered unrelated to study treatment. The most frequently reported AEs in both trials were COVID-19 and nasopharyngitis and headache. The proportion of patients reporting AEs leading to discontinuation of study treatment was lower in the diclofenac cream treatment groups compared to the respective cream vehicle groups (DELTA 1 : 0.6%; DELTA 2: 0.3%). In DELTA 1 and DELTA 2, the results were similar across all study groups and the measures taken after the occurrence of AEs using the study medication (Table 12). Figure 7 ). In both studies, very few serious AEs were reported (< 1.9% of patients) and all were assessed by the investigator and sponsor as unrelated to study medication; none raised any safety concerns. No specific treatment-emergent safety concerns were identified in DELTA 1 and DELTA 2. No AEs of particular interest (herpes simplex eczema, deep vein thrombosis or pulmonary embolism) were reported in DELTA 1 and DELTA 2. In both studies, no major adverse cardiac events were reported in the diclofenac treatment groups. There were no changes or differences assessed as clinically relevant between treatment groups in haematology, biochemistry, vital signs, physical examination or ECG.
[0672] In DELTA 1 and DELTA 2, at Week 1, 41.9-47.2% of patients treated with diclofenac cream and 36.9-41.2% of patients treated with cream vehicle did not experience stinging or burning sensation, at Week 16, the proportion of patients increased to 90.0-91.7% (diclofenac cream) and 88.6-91.8% (cream vehicle) (Table 13).
[0673] Table 13. Weekly local tolerability assessment of the most severe stinging or burning sensation associated with the application of study medication assessed by the study participant at the selected week a (Safety Analysis Set)
[0674]
[0675] a Assessed weekly in the electronic diary.
[0676] N, number of patients in the analysis set; n, number of patients with an observation.
[0677] From Week 1 onwards, numerically higher proportions of patients treated with diclofenac cream reported no or mild tolerability issues compared with the cream vehicle group. Diclofenac cream was well tolerated in both trials according to investigator assessment of local tolerability (Table 14). Very few subjects had patch tests (DELTA 1 : n = 2 [diclofenac cream] and n = 4 [cream vehicle]; DELTA 2: n = 1 [diclofenac cream] and n = 4 [cream vehicle]) during the study.
[0678] Table 14. Investigator assessment of local tolerability based on suspected local skin reactions related to study drug application at visits (safety analysis set)
[0679]
[0680] From baseline to end of trial, numerically higher proportions of all AEs, AEs related to study drug, and AEs leading to discontinuation of study drug were reported for the cream vehicle compared with diclofenac.
[0681] Overall, diclofenac cream was associated with greater improvement in patient- and clinician-reported efficacy outcomes compared with the cream vehicle and was well tolerated for 16 weeks.
[0682] Example 2
[0683] A phase 3 randomized, double-blind, vehicle-controlled, parallel-group, multicenter clinical trial designed to confirm the efficacy of diclofenac cream 20 mg / g twice daily compared with the cream vehicle and to assess safety in adult subjects with moderate to severe chronic hand eczema for a treatment period of 16 weeks (DELTA 2).
[0684] Subjects
[0685] A total of 473 subjects were randomized in a 2: 1 ratio to diclofenac cream 20 mg / g (314) or cream vehicle (159).
[0686] Inclusion and exclusion criteria were the same as in Example 1.
[0687] Investigational medicinal product (IMP) and administration of the IMP were the same as in Example 1.
[0688] Trial design was the same as in Example 1.
[0689] Results: At Week 16, a significantly greater proportion of patients treated with dermcidin cream achieved IGA-CHE TS (29.1% vs. 6.9%; p < 0.001), HECSI-75 (49.5% vs. 18.2%; p < 0.001), HECSI-90 (31.0% vs. 8.8%; p < 0.001), and DLQI improvement of >4 points (72.2% vs. 45.8%; p < 0.001) compared with the cream vehicle. There were no differences between dermcidin and cream vehicle in the proportion of patients reporting adverse events (AEs; 45.7% vs. 44.7%) and serious AEs (1.6% vs. 1.9%). The proportion of AEs assessed as likely or probably related to study drug was consistent between dermcidin (31.29 per 100-patient years of observation [PYO]) and cream vehicle (30.87 per 100 PYO). Cream vehicle resulted in a numerically higher proportion of AEs leading to discontinuation of study drug (11.02 per 100 PYO) compared with dermcidin (1.04 per 100 PYO).
[0690] Overall, dermcidin cream demonstrated greater improvement in patient- and clinician-reported efficacy outcomes compared with the cream vehicle and was well tolerated through Week 16. These results are consistent with previously reported results from the DELTA 1 study (Example 1) of the same design.
[0691] Study of Systemic Exposure:
[0692] Blood samples collected 2-6 hours after application of study medicinal product at Weeks 1, 4, and 16 were used to analyze plasma concentrations of dermcidin using a liquid chromatography / mass spectrometry-based method with a lower limit of quantification of 5 pg / ml. The 50% inhibitory concentration (IC50) of dermcidin in whole blood of healthy volunteers (n = 4) was assessed using an in vitro IL-4 release assay. In the Phase 1 trial, single oral doses of dermcidin (1.5, 3, 6, and 12 mg) were tested in healthy volunteers (n = 40). Data are reported as geometric mean.
[0693] Results: The DELTA 2 analysis included samples from 313 subjects who received active treatment. Plasma concentrations of dermcidin were 0.21, 0.20, and 0.12 ng / ml at Weeks 1, 4, and 16, respectively. The IC50 of dermcidin was 17.2 ng / ml. In the Phase 1 study, the lowest tested oral dose of dermcidin (1.5 mg) was considered a subtherapeutic dose. The peak systemic exposure (Cmax) of dermcidin administered orally at 1.5 mg was 7.2 ng / ml, which means that systemic exposure after topical application in the DELTA 2 trial was >30-fold lower (7.2 ng / ml divided by 0.21 ng / ml).
[0694] Conclusion: Twice-daily application of diclofenac cream resulted in minimal systemic exposure, with whole blood IC50 at least 80-fold lower (17.2 ng / ml divided by 0.21 ng / ml) over 16 weeks and at least 30-fold lower than an oral 1.5 mg diclofenac dose, with no overlap in plasma exposure between oral and topical administration. These data further support the good safety profile of topical diclofenac cream and indicate that use of a 20 mg / g dose is not expected to produce systemic pharmacological effects for moderate to severe CHE patients.
[0695] Example 3
[0696] DELTA 1 and DELTA 2 were multicenter, phase 3 trials of identical design in which adult patients with moderate to severe CHE were randomized (2:1) to double-blind treatment with diclofenac cream 20 mg / g or cream vehicle twice daily for 16 weeks. In a pooled analysis of both trials, change from baseline to Week 16 in EQ-5D score was evaluated in all patients and in a post-hoc analysis of patients achieving clinical response (defined as Hand Eczema Area and Severity Index (HECSI)-50, -75, and -90, Investigator’s Global Assessment of CHE Treatment Success [IGA-CHE TS; skin clear or almost clear with improvement of >2 steps from baseline], and Hand Eczema Symptom Diary (HESD) pruritus and pain score improvement of >4 points).
[0697] Results:
[0698] In both trials, a total of 639 patients were randomized to diclofenac cream 20 mg / g and 321 patients were randomized to cream vehicle. The majority of patients were White (90%) and female (64%), with moderate baseline CHE disease severity (72%). At baseline, the mean ± SD EQ-5D score was 0.65 ± 0.23 in the diclofenac group and 0.64 ± 0.24 in the cream vehicle group. At Week 16, treatment with diclofenac resulted in a significantly greater improvement from baseline in EQ-5D compared with cream vehicle (least squares mean change [SE] 0.17 ± 0.01 vs 0.06 ± 0.01; difference [95% Cl] 0.11 (0.08, 0.13), p < 0.001) Figure 10). EQ-5D improvements were significantly greater with diclofenac than with cream vehicle across all five EQ-5D dimensions (mobility, self-care, usual activities, pain / discomfort, and anxiety / depression). When analyzed by clinical response, there were clinically meaningful changes in EQ-5D (minimal important difference > 0.082) across different responder thresholds, suggesting that improvements in HRQoL can be associated with clinical response. Furthermore, EQ-5D improvements were consistently higher with diclofenac than with cream vehicle across each clinical responder group, all with statistical significance except for the IGA-CHE TS category. In addition, significantly more patients treated with diclofenac achieved clinical response across different clinical responder thresholds.
[0699] CONCLUSIONS:
[0700] In patients with moderate to severe CHE and severely impaired HRQoL, twice-daily treatment with diclofenac cream 20 mg / g for 16 weeks produced statistically significantly greater improvements in clinical outcomes and in HRQoL, as measured by EQ-5D scores, than cream vehicle. Patients who achieved clinical response across various responder thresholds experienced even greater HRQoL benefits with diclofenac treatment than with cream vehicle. This HRQoL improvement was considered clinically meaningful.
[0701] Example 4
[0702] DELTA 1 and DELTA 2 were phase 3 trials of identical design. In both trials, adult patients with moderate to severe CHE were randomized (2:1) to double-blind treatment with diclofenac cream 20 mg / g or cream vehicle twice daily for 16 weeks. Data from both trials were pooled, and changes in DLQI scores from baseline to Week 16 were evaluated in all patients and in post hoc analyses of patients who achieved clinical response, defined as HECSI-50, -75, and -90, Investigator’s Global Assessment of CHE Treatment Success (IGA-CHE TS; score of 0 / 1 with > 2-step improvement from baseline), and HESD pruritus and pain score improvement of > 4 points.
[0703] Results:
[0704] In both trials, 639 patients were randomized to diclofenac cream 20 mg / g, and 321 patients were randomized to vehicle cream. The majority of patients were white (90%), female (64%), and the mean duration of CHE was approximately 10 years. At baseline, the mean ± SD DLQI score was 12.4 ± 6.1 in the diclofenac group and 12.4 ± 6.7 in the cream vehicle group. At Week 16, diclofenac resulted in a significantly greater improvement (i.e., reduction) in DLQI from baseline compared to cream vehicle (least squares mean change [SE] -7.25 ± 0.22 vs. -3.46 ± 0.31; difference [95% Cl] -3.79 (-4.55, -3.04), p < 0.001) Figure 11 ). Across all ten DLQI items, the improvement in DLQI at Week 16 using diclofenac was significantly greater than cream vehicle (p < 0.001), particularly for items related to embarrassment or self-consciousness about the skin and the impact on work, social and leisure activities, and other daily activities. When analyzed by clinical response, the improvement in DLQI using diclofenac was observed to be greater than cream vehicle across all clinical responder categories, and all but HECSI-90 and IGA-CHE TS, with statistical significance. In addition, a higher proportion of patients treated with diclofenac achieved a clinical response compared to cream vehicle as assessed in all responder thresholds (all p < 0.001).
[0705] Conclusions:
[0706] Application of diclofenac cream 20 mg / g twice daily resulted in a significant improvement in HRQoL compared to cream vehicle as measured by DLQI in patients with moderate to severe CHE. In patients with a clinical response, the benefit of diclofenac on HRQoL was greater than cream vehicle.
[0707] Example 5
[0708] A Phase 3 clinical trial to evaluate the efficacy and safety of diclofenac cream 20 mg / g applied twice daily compared to cream vehicle in adolescents 12-17 years of age with moderate to severe chronic hand eczema for a treatment period of 16 weeks (DELTA TEEN).
[0709] Subjects
[0710] Approximately 92 subjects will be randomized in a 3: 1 ratio to diclofenac cream 20 mg / g or cream vehicle.
[0711] Inclusion Criteria
[0712] Same as Example 2, except the following inclusion criteria:
[0713] 1. Signed and dated IC has been obtained prior to any protocol-related procedures. Signed and dated IC must be provided by the subject’s parent / guardian and / or by the subject in the form of a signed and dated IC / IA (as applicable according to national laws or regulations).
[0714] 2. Age 12 to 17 years at screening and at baseline.
[0715] 3. HESD Pruritus Score (weekly mean) > 4 at baseline. Baseline weekly mean is calculated from daily pruritus severity assessments during the 7 days immediately preceding the baseline visit (Day -7 to Day -1). Seven days of at least 4 pruritus scores are required to calculate the baseline mean score.
[0716] Exclusion Criteria
[0717] Same as Example 1, except the following:
[0718] Subject or parent / guardian currently or recently chronically abusing alcohol or drugs, or any other condition in the investigator’s judgment that is associated with poor compliance.
[0719] IMP
[0720] Investigational Medicinal Product (IMP)
[0721] The active IMP and placebo IMP are shown below:
[0722]
[0723] Excipients and cream vehicle for Diclofenac Cream 20 mg / g are the same as in Example 1.
[0724] The IMP (Diclofenac Cream 20 mg / g or Cream Vehicle) is applied as a topical application, twice daily, approximately 12 hours apart, for 16 weeks.
[0725] Study Outline
[0726] This trial is a Phase 3, randomized, double-blind, vehicle-controlled, parallel-group, multi-site trial. The trial aims to evaluate the efficacy and safety of Diclofenac Cream 20 mg / g applied twice daily for 16 weeks in adolescents 12-17 years of age with moderate to severe chronic hand eczema.
[0727] Screening Period (-4 Weeks to Week 0)
[0728] The screening period is a minimum of 1 week and a maximum of 4 weeks (i.e. screening visits should be performed between Week -4 and Week -1). For subjects using a treatment listed as an exclusion criterion, the duration of the screening period will depend on the required washout period. Given that the washout period for some of these treatments is 28 days and the allowed visit window is +3 days, the screening period is extended up to 31 days. Only subjects who are deemed able to stop the prohibited treatment during the screening period and who do not experience intolerable worsening of CHE signs and symptoms will be included in the trial.
[0729] At the screening visit, the subject’s eligibility to participate in the trial is checked. Trial-specific measurements will be performed as outlined in the trial procedure schedule.
[0730] The subject’s CHE subtype will be classified according to standard clinical practice in Europe, Canada and Australia.
[0731] Treatment Period (Week 0 to Week 16)
[0732] At baseline (Day 1), the subject’s eligibility to participate is confirmed. Eligible subjects are randomly assigned in a 3:1 ratio to either degarelix cream 20 mg / g or cream vehicle.
[0733] The subject / caregiver applies the IMP (degarelix cream 20 mg / g or cream vehicle) twice daily for 16 weeks. The first IMP application at the trial site is performed at baseline (Day 1) after all baseline assessments have been performed. All subsequent IMP applications are performed by the subject / caregiver at home.
[0734] During the 16-week treatment period, the subject returns to the trial site for efficacy and safety assessments.
[0735] Follow-up Period (Week 16-18)
[0736] Approximately 2 weeks after the last IMP application, the subject is followed up by telephone (which can be an on-site visit) to assess safety. Note that for subjects who stopped IMP treatment early, the 2-week follow-up period starts at the time of the last IMP application.
[0737] Endpoints
[0738] The endpoints of the trial are disclosed in Tables 9 and 10 above.
[0739] Example 6
[0740] Two different formulations containing degarelix were tested in the following:
[0741] I) Human skin explant (Native Skin) biomarker testing and
[0742] II) Open-flow microperfusion (OFM) in pigs to explore the PKPD profile of decernotinib in different test systems.
[0743] Formulations Tested
[0744] Ointment: 30 mg / g decernotinib ointment as disclosed in D1 (WO2017 / 125523)
[0745] Cream: 20 mg / g decernotinib cream formulation as disclosed in the filed patent application (WO2020229622)
[0746] Human Skin Ex vivo Biomarker Testing
[0747] Both formulations were tested in the NativeSkin model from Genoskin, France (LEO Pharma A / S experiment number EXP-2017-6909). The biomarker for JAK inhibition, the ratio of phosphorylated STAT3 / total STAT3 (pY-STAT3 / STAT3), was measured 24 hours after application of the ointment (30 mg decernotinib / g) or the cream (20 mg decernotinib / g) and compared to control cream and blank (3 different donors for each treatment).
[0748] The results are shown in Figure 8
[0749] The cream formulation of decernotinib inhibited the upregulation of the pY-STAT3 / STAT3 ratio significantly more than the ointment Figure 3 , which indicates that significantly more decernotinib penetrates into the skin from the 20 mg / g cream of the present invention compared to the 30 mg / g ointment described in WO2017 / 125523.
[0750] Open Flow Microperfusion
[0751] Both formulations were tested in vivo in long white pigs at the Joanneum Research Institute, Austria (LEO Pharma A / S report number REP-DJR-2018-01). The concentration of decernotinib in the dermis was measured by using OFM up to 12 hours after application of the ointment (30 mg decernotinib / g) or the cream (20 mg decernotinib / g) Figure 9 .
[0752] The unbound concentration of dacomitinib in the dermal interstitial fluid was calculated from the perfusate concentration set to recover relative to the in vitro measured protein binding. Two pigs were treated, each pig having two test fields for each formulation and three probes inserted per test field (n = 12 individual probes per treatment).
[0753] The unbound dermal interstitial fluid (dISF) concentration of dacomitinib was higher after application of the cream formulation compared to the ointment Figure 3 ). The dISF concentration after application of the cream was significantly higher compared to the unbound potency, indicating that more dacomitinib penetrated into the skin from the 20 mg / g cream compared to the 30 mg / g ointment, which is consistent with the inhibition of the biomarker seen in human skin explant experiments.
[0754] Example 7
[0755] Pruritus and pain are the two most common and burdensome symptoms of chronic hand eczema. Dacomitinib cream is a topical pan-Janus kinase inhibitor, well tolerated in DELTA-1 and DELTA-2, and showed significant improvement in all primary and secondary efficacy endpoints.
[0756] This analysis included pooled data from DELTA-1 and DELTA-2 (dacomitinib cream 20 mg / g [n = 639]; cream vehicle [n = 321]; twice daily). The Hand Eczema Symptom Diary (HESD) recorded the severity of patient-reported pruritus and pain over the past 24 hours on an 11-point numerical rating scale (0 = no pruritus / pain to 10 = severe pruritus / pain). Changes in pruritus and pain from baseline were assessed daily during Week (W) 1 and weekly from W1-16.
[0757] For pruritus, the least squares (LS) mean reductions from baseline between Day 1-7 (D) were 0.22-1.32 for the diclofenac cream group and 0.21-0.68 for the cream vehicle group. For pain, LS mean reductions from baseline of 0.13-1.43 versus 0.26-0.81 were observed, respectively. From Wl-16, diclofenac treated patients achieved higher LS mean reductions from baseline in pruritus scores (1.0-3.5) compared to patients receiving cream vehicle (0.4-1.7; P<0.001). Similar results were seen for LS mean pain reduction (diclofenac cream: 0.9-3.3; cream vehicle: 0.4-1.5; P<0.001). In patients with baseline HESD pruritus / pain scores of >4, the proportion of diclofenac cream treated patients achieving a reduction of >4 in HESD pruritus / pain scores from baseline was higher than patients treated with cream vehicle from W2-16 (P<0.001).
[0758] For diclofenac treated patients, early onset of pruritus and pain reduction was observed within Wl and the degree of reduction remained significantly higher than in cream vehicle treated patients from Wl to Wl 6.
[0759] Example 8
[0760] In the Phase 3 trial of DELTA 2, diclofenac cream 20 mg / g (topical pan-Janus kinase inhibitor) was well tolerated and demonstrated significant improvements in all efficacy endpoints compared to cream vehicle in adults with moderate to severe chronic hand eczema (CHE).
[0761] Pharmacokinetic blood sampling (lower limit of quantification: 5 pg / ml) was performed in DELTA 2 using a liquid chromatography / mass spectrometry-based method at 1, 4, and 16 weeks, 2-6 hours after diclofenac application. In the Phase 1 trial (NCT05050279), a single oral dose of diclofenac was tested in healthy volunteers and sampling was performed up to 24 hours after administration.
[0762] In Delta 2, the maximum plasma concentration (C max ) and area under the concentration-time curve (AUC 0-12 ) from 0 to 12 hours on Day 8 were 0.46 ng / ml + / - 0.28 and 3.7 ng*h / ml + / - 1.88, respectively. Steady state was reached by Day 8. Systemic exposure (AUC and C max ) was similar and negligible between Day 1 and Day 8.
[0763] In DELTA 2, minimal systemic exposure was documented in 313 patients treated with digoxin, with the highest geometric mean plasma concentration of 0.21 ng / ml at week 1 (n=286). By week 16, systemic absorption was detected in only some patients, and the detectable absorption was reduced by 48% in the remaining subjects, to a mean of 0.11 ng / ml. In the phase 1 trial, the lowest oral digoxin dose tested (1.5 mg; n=8) was considered a subtherapeutic dose and showed a peak systemic exposure (geometric mean Cmax) of 7.2 ng / ml. In DELTA 2, 45.7% (n = 143 / 313; digoxin cream) and 44.7% (n=71 / 159; cream vehicle) of patients reported adverse events (AEs), with the most common being COVID-19 (11.5% vs 12.6%, respectively). The rate of possibly or probably related AEs was low and similar between digoxin cream and cream vehicle. No deaths were reported. SAEs were rarely reported and none was assessed as related to study drug.
[0764] The plasma protein binding of digoxin was 22 to 29%.
[0765] Following repeated topical application of digoxin cream, the mean half-life of digoxin was estimated to be 20.3 hours.
[0766] The DELTA 2 trial demonstrated minimal systemic exposure associated with a favorable safety profile, which supports that twice-daily application of digoxin cream in patients with moderate to severe CHE does not result in meaningful systemic effects.
Claims
1. A method of treating moderate to severe chronic hand eczema in a human patient in need thereof, comprising applying to the skin of the human patient twice a day an acidified aqueous topical composition comprising 20 mg / g of deguelin or a pharmaceutically acceptable salt thereof on a free base basis, wherein, According to IGA-CHE, the patient has a disease severity graded as moderate to severe (i.e., IGA-CHE score of 3 or 4) at screening and at baseline.
2. The method of claim 1, wherein, The patient has a HESD pruritus score (weekly mean) of >4 at baseline.
3. The method of any one of claims 1-2, wherein, The patient is a juvenile between 12 and 17 years of age or an adult of 18 years of age or older; wherein the patient has hand eczema that has persisted for more than 3 months or hand eczema that has recurred two or more times in the past 12 months.
4. The method of any one of claims 1-3, wherein, The patient has a documented history of inadequate response to topical corticosteroid (TCS) therapy, or TCS is documented as medically inadvisable for the patient for other reasons (due to major side effects or safety risks).
5. The method of any one of claims 1-4, wherein, At Week 16, the patient achieves an IGA-CHE score of 0 (cleared) or 1 (almost cleared) with an improvement of >2 steps from baseline.
6. The method of claim 5, wherein, At Week 8, the patient achieves an IGA-CHE score of 0 (cleared) or 1 (almost cleared) with an improvement of >2 steps from baseline.
7. The method of claim 5, wherein, At Week 4, the patient achieves an IGA-CHE score of 0 (cleared) or 1 (almost cleared) with an improvement of >2 steps from baseline.
8. The method of claim 5, wherein, At Week 2, the patient achieves an IGA-CHE score of 0 (cleared) or 1 (almost cleared) with an improvement of >2 steps from baseline.
9. The method of claim 5, wherein, At Week 1, the patient achieves an IGA-CHE score of 0 (cleared) or 1 (almost cleared) with an improvement of >2 steps from baseline.
10. The method of any one of claims 1-9, wherein, At Week 16, or Week 8, or Week 4, Week 2 or Week 1, the patient achieves at least 90% improvement in HECSI score from baseline.
11. The method of any one of claims 1-9, wherein, At Week 16, or Week 8, or Week 4, or Week 2 or Week 1, the patient achieves at least 75% improvement in HECSI score from baseline.
12. The method of any one of claims 1-11, wherein, The patient has a baseline HESD score (weekly mean) of >4 and achieves a reduction of >4 in HESD score (weekly mean) from baseline at Week 16.
13. The method of claim 12, wherein, The patient has a baseline HESD score (weekly mean) of >4 and achieves a reduction of >4 in HESD score (weekly mean) from baseline at Week 12.
14. The method of claim 13, wherein, The patient has a baseline HESD score (weekly mean) of >4 at baseline and achieves a reduction of >4 in HESD score (weekly mean) from baseline at Week 8.
15. The method of claim 13, wherein, The patient has a baseline HESD score (weekly mean) of >4 at baseline and achieves a reduction of >4 in HESD score (weekly mean) from baseline at Week 4.
16. The method of claim 13, wherein, The patient has a baseline HESD score (weekly mean) of >4 at baseline and achieves a reduction of >4 in HESD score (weekly mean) from baseline at Week 2.
17. The method of claim 13, wherein, The patient has a baseline HESD score (weekly mean) of >4 at baseline and achieves a reduction of >4 in HESD score (weekly mean) from baseline at Week 1.
18. The method of any one of claims 1-17, wherein, The patient has a baseline HESD pruritus score (weekly mean) of >4 points, and achieves a reduction of >4 points in HEDS pruritus score (weekly mean) from baseline at Week 16.
19. The method of claim 18, wherein, The patient has a baseline HESD pruritus score (weekly mean) of >4 points, and achieves a reduction of >4 points in HEDS pruritus score (weekly mean) from baseline at Week 8.
20. The method of claim 18, wherein, The patient has a baseline HESD pruritus score (weekly mean) of >4 points, and achieves a reduction of >4 points in HEDS pruritus score (weekly mean) from baseline at Week 4.
21. The method of claim 18, wherein, The patient has a baseline HESD pruritus score (weekly mean) of >4 points, and achieves a reduction of >4 points in HEDS pruritus score (weekly mean) from baseline at Week 2.
22. The method of claim 18, wherein, The patient has a baseline HESD pruritus score (weekly mean) of >4 points, and achieves a reduction of >4 points in HEDS pruritus score (weekly mean) from baseline at Week 1.
23. The method of any one of claims 1-22, wherein, The patient has a baseline HESD pain score (weekly mean) of >4 points, and achieves a reduction of >4 points in HESD pain score (weekly mean) from baseline at Week 16.
24. The method of any one of claims 1-22, wherein, The patient has a baseline HESD pain score (weekly mean) of >4 points, and achieves a reduction of >4 points in HESD pain score (weekly mean) from baseline at Week 8.
25. The method of claim 24, wherein, The patient has a baseline HESD pain score (weekly mean) of >4 points, and achieves a reduction of >4 points in HESD pain score (weekly mean) from baseline at Week 4.
26. The method of claim 24, wherein, The patient has a baseline HESD pain score (weekly mean) of >4 points, and achieves a reduction of >4 points in HESD pain score (weekly mean) from baseline at Week 2.
27. The method of claim 24, wherein, The patient has a baseline HESD pain score (weekly mean) of >4 points, and achieves a reduction of >4 points in HESD pain score (weekly mean) from baseline at Week 1.
28. The method of any one of claims 1-27, wherein, The patient achieves a reduction of >4 points in DLQI score from baseline at Week 16.
29. The method of claim 28, wherein, The patient achieves a reduction of >4 points in DLQI score from baseline at Week 8.
30. The method of claim 28, wherein, The patient achieves a reduction of >4 points in DLQI score from baseline at Week 4.
31. The method of claim 28, wherein, The patient achieves a reduction of >4 points in DLQI score from baseline at Week 2.
32. The method of claim 28, wherein, The patient achieves a reduction of >4 points in DLQI score from baseline at Week 1.
33. The method of any one of claims 1-32, wherein, No accumulation of digoxin was observed in vivo.
34. The method of any one of claims 1-33, wherein, The administration to the skin of a human patient is administration to the hands and wrists of a human patient.
35. The method of any one of claims 1-34, wherein, The treatment is continued until the patient achieves clearance or near-clearance of the skin.
36. The method of claim 35, wherein, In case of recurrence of (flare-up) signs and symptoms, the treatment of the affected areas is resumed twice daily as needed.
37. The method of any one of claims 1-36, wherein, Digoxin is dissolved in the aqueous phase of the topical formulation.
38. The method of any one of claims 36-37, wherein, The aqueous topical formulation has a pH lower than about 4.6 or lower than about 4.
4.
39. The method of claim 38, wherein, The aqueous topical formulation has a pH of about 3.8 to about 4.
6.
40. The method of claim 39, wherein, The aqueous topical formulation has a pH of about 4.3 or lower.
41. The method of claim 39, wherein, The aqueous topical formulation has a pH of about 4.2 or less.
42. The method of any one of claims 37-41, wherein, The aqueous cream comprises a lipid base.
43. The method of claim 42, wherein, The lipid base is liquid paraffin.
